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ABSTRACT 
Aging is a complex process that occurs as we grow old and is associated with a gradual decline of 
tissue functions. Scientists have been trying to understand the mechanisms that drive such 
phenomenon by studying premature aging syndromes and aging-related disorders. The Hutchinson-
Gilford progeria syndrome (HGPS) is a lethal segmental genetic disease affecting children at an early 
age and characterized by accelerated aging-like features including alopecia, loss of subcutaneous 
adipose tissue and cardiovascular pathologies. This disorder primarily results from the production of 
a noxious protein called progerin, altering proper tissue homeostasis and functions. Strikingly, HGPS 
children present an accelerated vascular aging phenotype similar to that of chronic kidney disease 
(CKD) patients. Indeed, in addition to displaying kidney defects, CKD patients exhibit an accelerated 
vascular decline. Interestingly, progerin has previously been found expressed in cells and tissues 
from aged individuals, but its contribution to aging and aging-associated disorders remains poorly 
understood. Here, we investigated whether and how various levels of progerin are relevant to the 
development and progression of tissue pathology in HGPS, normal aging and aging-associated 
diseases, in order to generate a potential new treatment strategy for HGPS in particular. 
In paper I, to better understand the mechanisms by which progerin accumulation disrupts tissue 
homeostasis, a humanized HGPS mouse model with overexpression of progerin in the skin was used. 
We demonstrated that progerin accumulation resulted in impaired tissue homeostasis as a 
consequence of an aberrant increase in symmetric cell division. Further analysis suggested a 
potential causal role of the Wnt/β-catenin signaling, associated with mislocalization of the nuclear 
envelope proteins emerin and nesprin-2. 
In paper II, to investigate whether a small fraction of progerin-expressing cells in a tissue can lead to 
tissue pathology during aging, another humanized HGPS mouse model was employed. We showed 
that continuous expression of progerin in only a few preadipocytes and adipocytes is associated with 
fibrosis and lipoatrophy over time. This phenotype was combined with increased senescence, 
persistent DNA damage and cell death, which were found accompanied by macrophage infiltration 
and systemic inflammation. These results suggested that progerin, despite being expressed in only a 
low fraction of the cells of a tissue, has the potential to contribute to a common aging-associated 
phenotype. 
In paper III, to unravel the possible involvement of progerin expression in age-associated diseases, we 
used arterial biopsies and blood from CKD patients. We found that progerin was expressed at low 
frequencies in 70% of the CKD patients arteries (in up to 7.4% of the cells), which was associated with 
an increase in DNA damage. When searching for the cause of progerin expression, we identified the 
LMNA c.1824C>T mutation in both the blood and arteries. Our data further suggested that progerin-
expressing cells might arise during vascular regeneration, by proliferation of progenitor cells. 
In paper IV, to examine the mechanisms associated with telomere dysfunction in HGPS, we employed 
various in vitro systems and a severe progeroid mouse model of skin. We demonstrated that telomere 
dysfunction leads to the production of non-coding RNAs, which activates the DNA damage response 
signaling. Treatment with telomeric sequence-specific antisense oligonucleotides not only repressed 
this signaling, but also significantly improved both the healthspan and lifespan of HGPS mice. 
This thesis provides novel findings about the complex molecular mechanisms underlying progerin 
expression in HGPS, and its possible contribution to aging and CKD-related early vascular aging, all of 
which led to the discovery of a potential new treatment approach for HGPS. 
RÉSUMÉ 
Le vieillissement est un processus complexe, associé à un déclin progressif des fonctions tissulaires. 
Divers syndromes de vieillissement prématuré ainsi que les maladies liées à l’âge sont souvent 
utilisés en recherche, afin d’étudier les mécanismes à l’origine du vieillissement. Le syndrome de 
Hutchinson-Gilford (HGPS ou progéria), est une maladie génétique mortelle qui affecte les enfants dès 
leur plus jeune âge. La maladie se distingue par plusieurs caractéristiques s’apparentant au 
vieillissement prématuré, telles que la perte de cheveux et de tissu adipeux sous-cutané, ou encore 
l’apparition de pathologies cardiovasculaires. Ce syndrome résulte principalement de la production 
d'une protéine toxique appelée progérine, qui altère l'homéostasie et les fonctions tissulaires. 
Étonnamment, les enfants atteints de progéria présentent un phénotype de vieillissement vasculaire 
prématuré similaire à celui de patients atteints d'insuffisance rénale chronique (IRC). En effet, en plus 
d’altérer les fonctions rénales, l’IRC est accompagnée d’un déclin vasculaire prématuré. Par ailleurs, 
plusieurs études ont montré que progérine était exprimée dans les cellules et les tissus de personnes 
âgées, cependant, sa contribution au vieillissement et aux maladies liées à l’âge reste mal comprise. 
Dans cette thèse, nous avons examiné comment différents niveaux d’expression de progérine 
peuvent influencer le développement de phénotypes couramment observés durant le vieillissement, 
mais aussi chez les patients atteints de progéria ou de maladies liées à l’âge, et ce afin de développer 
une nouvelle stratégie de traitement de la progéria. 
Dans le premier article, afin de mieux comprendre les mécanismes par lesquels l’accumulation de 
progérine perturbe l’homéostasie tissulaire, nous avons utilisé un modèle murin présentant une 
surexpression épidermale de progérine. Ainsi, nous avons montré que l'accumulation de progérine 
entraînait une perturbation de l'homéostasie tissulaire en conséquence d’une augmentation anormale 
de division cellulaire symétrique. Une analyse plus poussée a permis de suggérer l’implication de la 
voie de signalisation Wnt/β-caténine, associée à une délocalisation de deux protéines de l’enveloppe 
nucléaire: émerine et nesprine-2.  
Dans le second article, afin d’évaluer si seule une petite fraction de cellules exprimant progérine 
pouvait entraîner une pathologie tissulaire au cours du vieillissement, nous avons utilisé un autre 
modèle murin progéroïde présentant une perte de tissue adipeux sous-cutané. De ce fait, nous avons 
établi que l’expression continue de progérine dans seulement quelques préadipocytes et adipocytes 
était liée à une fibrose et à une lipoatrophie se développant au fil du temps. Ce phénotype était 
également associé à une sénescence accrue, à de persistants dommages à l'ADN ainsi qu’à la mort 
cellulaire, le tout étant accompagné par l’infiltration de macrophages au sein du tissu adipeux et d'une 
inflammation systémique. Ces résultats suggèrent que progérine, bien que seulement exprimée dans 
une faible fraction de cellules, a le potentiel de contribuer à un phénotype communément associé au 
vieillissement.  
Dans le troisième article, pour mieux comprendre la possible implication de l'expression de progérine 
dans les maladies associées à l'âge, nous avons utilisé des biopsies artérielles de patients atteints 
d’IRC. Ainsi, nous avons constaté que progérine était exprimée à faible fréquence chez 70% des 
patients atteints d’IRC (fréquence allant jusqu'à 7,4% des cellules), ceci étant associé à une 
augmentation de dommages à l'ADN. Lors de la recherche de la cause de cette expression de 
progérine, nous avons pu identifier la présence de la mutation du gène LMNA, c.1824 C>T,  dans les 
artères. Nos données suggèrent que les cellules exprimant progérine pourraient apparaître au cours 
de la régénération vasculaire, via la prolifération de cellules progénitrices.  
 
  
Dans le quatrième article, pour examiner les mécanismes liés au dysfonctionnement télomérique 
couramment observé chez les cellules de patients atteints de progéria, nous avons utilisé divers 
systèmes in vitro et un modèle murin de progéria. Nous avons ainsi démontré que le 
dysfonctionnement des télomères conduisait à la production d'ARN non codants, résultant en 
l’activation de la cascade de signalisation de la réponse aux dommages à l'ADN. L’utilisation 
d’oligonucléotides antisens et spécifiques aux ARN non-codants télomériques a non seulement 
permis de réprimer cette signalisation, mais aussi d’améliorer de manière significative la santé et la 
durée de vie des souris HGPS. 
Ainsi, cette thèse procure de nouvelles découvertes quant aux mécanismes moléculaires sous-jacents 
à l'expression de progérine dans le cas de la progéria, ainsi que sa contribution au vieillissement 
vasculaire prématuré lié à l’IRC. Ceci a également conduit à la découverte d'une potentielle nouvelle 
approche thérapeutique de la progéria. 
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1. INTRODUCTION 
 What is aging? 
 “Aging is an extraordinary process where you become the person you always should have 
been.” - David Bowie.  
Everyone is intrinsically acquainted with aging; however, everyone has their own 
representation of this phenomenon. We have all seen people age and noticed how it takes 
many forms and affects different individuals in distinct ways. Indeed, age-related symptoms 
differ from one another, and aging is usually accompanied by a gradual decline of tissue 
functions, presumably as a result of genetic and environmental factors. With aging comes a 
higher risk of developing age-associated disorders, which eventually lead to death. In 
essence, physiological aging is an inevitable complex multifactorial biological process. In 
order to improve the quality of life and health of the elderly population, the aging research 
field focuses its efforts in deciphering the various causes of such process. 
In the recent years, nine cellular and molecular hallmarks thought to contribute to aging have 
emerged1. These now widely accepted characteristics can be classified into three 
fundamentally interconnected categories: primary hallmarks, antagonistic hallmarks and 
integrative hallmarks. Primary hallmarks are defined as causes of damage and consist of 
genomic instability, telomere attrition, epigenetic alterations and loss of proteostasis. 
Antagonistic hallmarks on the other hand, are defined as responses to damage, which can 
have deleterious effects when exacerbated. These include cellular senescence, mitochondrial 
dysfunction and deregulated nutrient sensing. Finally, integrative hallmarks are comprised of 
stem cell exhaustion and altered intercellular communication, and correspond to hallmarks 
altering tissue function and homeostasis1. Yet, the precise interplay between these molecular 
mechanisms remains unelucidated and most of the underlying biological bases of aging are 
still not fully understood.  
Several approaches can be used to investigate the features of aging, of which the study of 
progeroid syndromes and age-associated diseases are prominent. Such studies not only 
provide a better insight into particular disease mechanisms, but may also give the potential to 
increase our knowledge about the molecular bases of physiological aging. 
 Progeroid syndromes 
Progeriod syndromes are a class of genetic disorders characterized by several features of 
premature-aging like phenotypes. These diseases mimic physiological aging and can be 
classified into two categories: unimodal and segmental. Unimodal progeroid syndromes 
represent accelerated-aging diseases such as xeroderma pigmentosum, where only a single 
tissue presents aspects of aging. Contrastingly, segmental progeroid syndromes constitute a 
family of diseases where multiple tissues are affected by defects characteristic of aging, 
including Werner syndrome or Hutchinson-Gilford progeria syndrome (HGPS)2.  
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Most of these disorders result from genetic mutations in genes involved in the DNA damage 
repair machinery or in the LMNA gene, which encodes constituents of the nuclear lamina3,4. 
The majority of these disorders are of particular interest in the field of aging as they can be 
very severe and in some cases lead to a shortened lifespan. Identification of causative genes 
and mechanisms are thought to be helpful in understanding the mechanisms driving aging. 
For that purpose, the most commonly investigated progeroid syndromes are Werner 
syndrome and HGPS, as they most resemble physiological aging. However, progeroid 
syndromes do not entirely replicate the biological changes frequently observed during aging. 
 Hutchinson-Gilford progeria syndrome 
With a reported incidence of one in 18 million newborns, the Hutchinson-Gilford progeria 
syndrome, commonly known as progeria (Online Mendelian Inheritance in Man (OMIM) 
#176670), is a very rare genetic disease characterized by clinical features resembling that of 
marked premature aging. The first recorded case in the literature, a boy presenting “a very 
peculiar withered or old-mannish look, all his features being thin and pinched”, was described 
in 1886 by Jonathan Hutchinson5. In 1895, the general practitioner mentioned briefly a second 
case that was then specifically depicted in 1897 by Hastings Gilford, who had followed this 
patient for several years until his death6. But it was not until 2003, more than a century later, 
that the genetic mutation and molecular basis responsible for this disease were discovered7,8. 
 Molecular basis of HGPS 
The LMNA gene & laminopathies 
HGPS is a lethal disorder, affecting children during their early years. It results from a single de 
novo point mutation in the LMNA gene. The LMNA gene (OMIM #150330) is located on 
chromosome 1q22 and consists of 12 exons. It encodes two major A-type lamin proteins: 
lamin A and lamin C. These two proteins are generated through alternative splicing within 
exon 10, along with the two minor isoforms lamin AΔ10 and lamin C2, and expressed in the 
eukaryotic nucleus of differentiated cells (Figure 1)9,10. Together with the B-type, lamins B1 
and B2, which are respectively encoded by the LMNB1 and LMNB2 genes during 
development, they represent the major components of the nuclear lamina, a fibrous protein 
network that underlines the surface of the inner nuclear membrane11. 
Over 450 mutations have been discovered in the LMNA gene, causing disorders termed as 
primary laminopathies12. Laminopathies are a group of heterogeneous genetic diseases 
caused by either de novo or inherited mutations and resulting in defects in the nuclear 
lamina. This term not only describes LMNA-related pathologies, but also encompasses 
diseases categorized as secondary laminopathies where mutations were found in genes 
encoding prelamin A-processing enzymes (such as ZMPSTE24), lamin-binding proteins (such 
as LAP2α, EMD, LBR, TMPO, LEMD3) or B-type lamins13-15. To date, there are more than a 
dozen diseases identified as laminopathies, which can be classified in five different categories: 
muscular dystrophies affecting striated muscles (such as Emery-Dreifuss muscular dystrophy 
or dilated cardiomyopathy type 1A), lipodystrophies affecting the adipose tissue (such as 
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mandibuloacral dysplasia), neuropathies affecting peripheral nerves (such as Charcot-Marie-
Tooth type 2 disease), segmental progeroid syndromes causing several tissues to age 
prematurely  (such as HGPS, restrictive dermopathy or atypical-Werner syndrome) and 
overlapping syndromes corresponding to pathologies whose symptoms appear to be in more 
than one category (such as Reynolds syndrome or Pelger-Huet anomaly)16. 
 
Figure 1. From gene to proteins: the LMNA gene. The LMNA gene is composed of 12 exons, which 
are alternatively spliced at exon 10, giving rise to two similar protein products: lamin A (exon 1-12) 
and lamin C (exon 1-10). Lamin proteins present a central α-helical rod domain, with a short 
globular head domain at the N-terminal extremity and a wide globular tail domain at the C-terminal 
extremity. 
Lamin A & progerin synthesis 
Just like B-type lamins, lamin A is primarily synthetized as a precursor protein called 
prelamin A. In order to reach its final mature form, the precursor must undergo several post-
translational modifications at its C-terminal CAAX motif (C: cysteine, A: aliphatic amino acid 
and X: any amino acid). In prelamin A, the CAAX sequence corresponds to cysteine, serine, 
isoleucine and methionine (CSIM)17.  
Prelamin A maturation occurs in four steps (Figure 2):  
(i) Farnesylation: prelamin A’s CSIM-cysteine is first farnesylated through the action 
of a farnesyltransferase (FTase).  
(ii) Initial proteolysis: the terminal three amino acids, -SIM, are cleaved by a 
metalloprotease (ZMPSTE24 or RCE1).  
(iii) Methylation: the farnesylated cysteine is methylated by an isoprenylcysteine 
carboxymethyl transferase (ICMT).  
(iv) Terminal proteolysis: mature lamin A is produced through an endoproteolytic 
cleavage of the last 15 amino acids by ZMPSTE24, including the farnesylated 
cysteine-methyl residue17,18.  
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Despite several mutations having been reported to cause HGPS, >90% of the cases are due to 
a de novo heterozygous substitution in exon 11 of the LMNA gene, the c.1824C>T8,19,20. This 
mutation is dominant in codon 608 and causes a substitution from GGC (glycine) to GGT 
(glycine), known as p.G608G. Despite being a silent mutation, it induces the activation of a 
cryptic splice donor site that leads to the lamin A transcript being spliced five nucleotides 
upstream of the mutation, creating a truncated mRNA lacking 150 nucleotides: lamin A Δ150. 
This, in turn, results in a truncated protein called lamin A Δ50, commonly named progerin, 
which contains a 50 amino-acid deletion (Val607_Gln656del) near its C-terminal region.  
 
Figure 2. Lamin A & progerin synthesis. After the splicing event occurred, the maturation of 
prelamin A to mature lamin A takes place, involving several post-translational modifications. In 
HGPS, aberrant splicing leads to the deletion of 50 amino acids (AA), including the recognition site 
of ZMPSTE24 (RSYLLG), and the final processing step cannot be performed, thus resulting in a 
truncated form of prelamin A: progerin. 
Like lamin A, progerin is produced from the prelamin A precursor. This truncated prelamin A 
undergoes the same post-translational modifications except for the terminal proteolysis step 
by ZMPSTE24, as the deleted 50 amino acids were containing the protease recognition site 
(RSYLLG motif). This results in a partially processed and toxic protein that remains 
farnesylated and carboxymethylated, called progerin (Figure 2). Of note, both mature lamin A 
and progerin proteins are generated from the mutant allele as the cryptic splice site is not 
continuously activated21,22. 
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 Nuclear & cellular defects in HGPS 
The nuclear envelope & the nuclear lamina 
The nucleus contains the genetic material and is associated with the cytoskeleton and 
cytoplasm through a bilayer nuclear envelope (NE) in eukaryotic cells. The NE is composed 
of two lipid membranes, the inner and outer nuclear membranes (INM and ONM, 
respectively), in between which lies the narrow perinuclear space. Although both the INM 
and ONM are functionally and biochemically different, they merge at sites that are crossed by 
nuclear pore complexes (NPCs). NPCs allow the bidirectional translocation of 
macromolecules, such as mRNAs, ribosomes, proteins, lipids and signaling molecules, 
between the nucleus and the cytoplasm23. The ONM is coated with ribosomes, as it is 
continuous to the rough endoplasmic reticulum, and both the ONM and INM contain various 
proteins that are embedded within their lipids, including lamina-associated proteins and LINC 
(Linker of Nucleoskeleton and Cytoskeleton) complex proteins (Figure 3)11,24.  
Directly underneath the INM lie the A- and B-type lamins, type V intermediate filament 
proteins constituting the nuclear lamina. The lamina plays an essential role in the cell as a 
structural support to the NE. It defines the size and shape of the nucleus through A-type 
lamins, which provide nuclear stiffness and viscosity, and B-type lamins, which provide 
elasticity25. Moreover, the nuclear lamina also takes part in gene regulation and transcription 
via its binding to chromatin and transcription factors, in cell differentiation, DNA replication 
and repair, and in NE assembly16,26-30.  
 
Figure 3. The role of the nuclear lamina at the nuclear envelope. The nuclear lamina is located at 
the nuclear rim, beneath the inner nuclear membrane (INM), where it confers support and stability 
to the nucleus. Lamins anchor chromatin but also have numerous binding partners among the 
nuclear envelope proteins (e.g. LAP1/2, LBR, SUN1/2, SAMP1, MAN1, emerin) and can indirectly 
interact with the cytoskeleton via the LINC complex (formed by SUN1/2 and nesprins1/2), thus 
influencing various biological processes31. 
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Lamins bind to numerous proteins, the vast majority being anchored to the INM. A few 
examples are the well-characterized lamin B receptor (LBR), lamina-associated polypeptides-1 
and 2α (LAP1 and LAP2α), nesprin-1α, MAN1, emerin, SUN1 and 2 proteins and SAMP1 
(Figure 3)32-35. Through its interaction with B-type lamins, LBR was suggested to be involved in 
chromatin tethering, epigenetic gene silencing and cell differentiation36-38. Similar to the LBR/B-
type lamins complex, the LAP2α/A-type lamins complex was found to influence cell 
differentiation and proliferation, as well as chromatin organization39-42. Lamins were also 
determined to play a crucial role in nesprin-1α, MAN1 and emerin localization at the NE, 
hence ensuring their important role in signal transduction, chromosome segregation and cell 
division and differentiation43-45.  
Meanwhile, emerin is also known to participate in transcriptional regulation, to bind to 
microtubules and stabilize actin filaments, suggesting that it can influence actin dynamics. 
Interestingly, emerin is also a binding partner of nesprin-1α11,46. Nesprins are embedded at the 
ONM and contain a KASH transmembrane domain, which interacts in the perinuclear space 
with the INM SUN proteins to form the LINC complex. This complex mechanically 
interconnects the nucleoskeleton and the cytoskeleton as SUN proteins bind to lamins while 
nesprins tether directly or indirectly structural cytoplasmic fibers such as actin, intermediate 
filaments, centrosomes or microtubules47-53. Of note, some isoforms such as nesprin-1α and 
nesprin-2β bind directly to lamins and emerin54,55. The combination of the LINC complex and 
nuclear lamins forms a protein network and was suggested to be implicated in the regulation 
of KASH binding and localization of nesprins to the NE, as well as in cell division, chromatin 
rearrangement and NPCs organization56,57. Furthermore, the A-type lamins interactor SAMP1 
was established as functionally co-localizing with SUN1, and was associated with the correct 
distribution of emerin and organization of heterochromatin at the nuclear periphery 34,58. This 
giant scaffold of interlinked proteins further highlights the central role of the nuclear lamina in 
fundamental biological processes. 
Nuclear & cellular alterations in HGPS 
Due to the toxic effect of progerin, HGPS recapitulates many of the nuclear and cellular 
defects commonly observed in physiological aging, including genomic instability, telomere 
shortening, epigenetic changes, senescence, stem cell exhaustion and mitochondrial 
dysfunction (Figure 4). Indeed, mutations in lamin A alter the natural functions of the nuclear 
lamina, including its primary function as a structural support to the NE. This results in cells 
exhibiting nuclear shape abnormalities known as nuclear blebs, which are accompanied by 
irregular localization of NPCs. It is thought that the aberrant processing of progerin contributes 
to its attachment to the INM, consequently leading to nuclear architectural defects22,28.  
In addition, the cell cycle, a valuable machinery for repairing genetic damage and avoiding 
uncontrolled cell divisions, is affected in HGPS cells. The cell cycle represents a continuous 
ordered series of events leading to cell growth and proliferation composed of three states: 
quiescence (G0 phase, where the cell ceases to divide), interphase (G1, S and G2 phases, 
where the cell grows and duplicates its genetic material in preparation of cellular division) 
and mitotic phase (M phase, including mitosis and cytokinesis, where the cell divides into two 
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identical daughter cells)59. Besides manifesting an impaired chromosome partitioning during 
mitosis, the onset and progression of cytokinesis is delayed, and the nuclear lamina 
components are abnormally segregated in the cytoplasm during the G1 phase in HGPS 
cells26,60.  
 
Figure 4. Shared cellular and molecular hallmarks between aging & HGPS. These nine cellular 
and molecular defects characterize the fundamental processes of HGPS pathogenesis and are 
commonly associated with physiological aging61. 
Tightly associated with the cell cycle is cellular senescence, a steady-state of cell cycle arrest 
mostly resulting from oxidative stress, DNA damage, telomere attrition or metabolic changes62. 
Progerin accumulation in HGPS cells and animal models generally correlates with increased 
senescence, and particularly with p53-dependent premature senescence63-65. Most often, 
senescence coincides with the production of inflammatory components that promote the 
expansion of senescence to neighboring cells in a paracrine manner. This process is termed 
the senescence-associated secretory phenotype (SASP) and participates in the activation of 
immune surveillance. Accordingly, inflammation is another defect associated with progeria. 
Indeed, levels of pro-inflammatory cytokines were found increased in three distinct progeroid 
mouse models and NF-κB-mediated inflammation was found to participate in the development 
of age-related features66,67. 
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HGPS cells are highly susceptible to genomic instability. They are especially characterized by 
impaired DNA damage-related mechanisms such as deficient DNA damage response (DDR) 
and double-strand breaks (DSBs) repair mechanisms, accelerated telomere shortening, 
epigenetic misregulation and changes in chromatin organization68. The recruitment of DDR 
molecules like RAD51 or 53BP1 at sites of DSBs appears delayed in HGPS, on top of which 
both homologous recombination and non-homologous end-joining repair pathways are 
suggested to be dysfunctional69,70. Meanwhile, the telomere loss observed in progeria may be 
explained by a decrease in TRF2 function, TRF2 being a lamin A binding partner stabilizing 
the formation of protective t-loops at telomeres63,71. Gene expression, on the other hand, is 
regulated by chromatin organization and epigenetic changes. In HGPS, cells exhibit reduced 
levels of HP1α, a protein involved in heterochromatin maintenance; along with lower levels of 
two epigenetic marks: H3K9me3 and H3K27me3. These deficiencies impede the maintenance 
of genome integrity through heterochromatin loss and repression of transcription30.  
One of the repercussions of DNA damage accumulation is that it can participate in the 
deterioration of stem cell functions, thus reducing tissue homeostasis and regeneration 
capacity. Progeroid stem cells exhibit alterations in their proliferative capacity as an 
indication of stem cell exhaustion67. Finally, various metabolic abnormalities are associated 
with HGPS. Affected pathways include glucose and fatty acid metabolism, oxidative 
phosphorylation and mitochondrial biogenesis, leading in some instances to mitochondrial 
dysfunction72-74. A notable example is the mechanistic target of rapamycin (mTOR) signaling 
pathway, which regulates anabolic and catabolic processes and is especially known to 
monitor cell growth, proliferation and autophagy. This pathway was found downregulated in 
HGPS, potentially resulting in autophagy activation72.  
 HGPS pathophysiology 
Children with HGPS display no evidence of disease at birth, however within their first years of 
life, they rapidly begin to develop age-like features. The mean age for diagnosis is 
approximately 2.6 years, as they start to show classical signs of illness. Failure to thrive and 
growth retardation are among the first clinical symptoms, and the classical phenotypes 
manifest in diverse organs: skin, adipose tissue, bones and cardiovascular system (Figure 5). 
The skin is affected with alopecia, revealing a prominent forehead and swollen scalp veins. It 
is subject to epidermal hypoplasia, a reduction in elasticity and scleroderma-like changes, 
accompanied by a loss of subcutaneous adipose tissue, thus resulting in tight and thin skin. 
Characteristic facial features include a pinched nose, thin lips and a shrunken chin (Figure 5). 
HGPS patients experience skeletal muscle wasting and their skeleton is marked by skeletal 
dysplasia, where the dentition is delayed and irregular, and a diminished bone mineral 
density. Joint stiffness and acro-osteolysis also occur as the children age, promoting limited 
joint mobility and contributing to the resorption of distal phalanges. Patients suffer from 
atherosclerosis and cardiovascular decline, eventually leading to death at an approximate age 
of 14.6 years75-77.  
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Figure 5. Clinical features of HGPS. HGPS patients display a strong phenotype characterized by 
clinical features resembling premature aging. Diagnosis can be based on the assessment of those 
features, which comprise growth retardation, alopecia, loss of subcutaneous fat, skeletal dysplasia 
and cardiovascular defects, among others. This figure was originally published in Strandgren et al., 
Biochem. Soc. Transac. (2017)78. 
These health problems are commonly shared with normal aging, however, and for unknown 
reasons, other aging disorders such as neurodegeneration and dementia, chronic kidney 
disease or diabetes do not occur (Figure 6). The absence of phenotype in certain tissues is 
actually a large and unexplored area in the HGPS research field. As for the lack of 
neurodegeneration, it is thought that the microRNA miR9 inhibits progerin expression in 
neural cells from HGPS patients, thus acting as a protection against brain-associated 
disorders79. However, a study conducted in our lab showed that long-term overexpression of 
progerin in the brain of mice did not result in a phenotype, indicating that progerin does not 
affect neuronal cells80. Neurons are post-mitotic cells, which could explain the fact that they 
appear to be insensitive to progerin expression. It can also be hypothesized that progerin 
expression may not be of importance in some other organs, those organs potentially being 
protected against the toxic effects of progerin in a similar fashion. The absence of phenotype 
in certain tissues might also be caused by the lack of significant levels of progerin expression 
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combined with the shortened lifespan of HGPS patients, as previously observed in some 
mouse models that fail to reproduce certain HGPS phenotypes likely as a consequence of low 
levels of progerin expression81,82. Despite the presence of considerable genomic instability, 
affected children do not develop cancer or tumors. This is probably due to a reduced 
invasive capacity of tumor-initiating cells caused by changes in extracellular matrix 
composition and/or due to a protective mechanism to oncogenesis associated with progerin 
expression83,84. HGPS being a segmental disease, organs including the liver, kidneys, brain, 
lungs and the gastrointestinal tract remain unaffected. In fact, it is worth noting that most 
affected tissues are of mesodermal and ectodermal origin.  
 
Figure 6. Shared phenotype between HGPS & aging. HGPS patients display many clinical features 
commonly observed during normal aging, including atherosclerosis or reduced bone mineral 
density. However, not all aging phenotypes are recapitulated in HGPS, and patients do not present 
neurodegeneration or cancer. This figure was originally published in Strandgren et al., Biochem. 
Soc. Transac. (2017)78. 
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The adipose tissue 
The mesoderm represents one of the three primary germ layers, which also include the 
ectoderm and the endoderm; and gives rise to mesenchymal tissues during embryogenesis. 
These tissues consist of connective or “soft” tissues, which can compose many organs and 
participate in their shape and strength. Seven major cell types are of mesenchymal origin, 
including adipocytes, fibroblasts, myoblasts, mesothelial cells, endothelial cells, 
chondroblasts and osteoblasts85-87. The development of these cell types occurs through the 
differentiation of mesenchymal stem cells, which are also referred to as multipotent stromal 
cells.  
The adipose tissue is one of the richest sources of mesenchymal stem cells. It is mainly 
composed of mature adipocytes, but also of various cell types forming the stromal vascular 
fraction, including preadipocytes, fibroblasts, endothelial cells (ECs) and hematopoietic cells. 
This connective tissue is found throughout the body and constitutes one of the largest organs. 
Different fat depots with distinct functions can be found in both humans and mice: the white 
adipose tissue (e.g. subcutaneous or visceral) and the brown adipose tissue88. The main 
function of brown adipose tissue is to generate body heat. Meanwhile, white adipose tissue is 
known to be involved in energy storage in the form of lipid, but also in immunity, and works 
as an endocrine organ, secreting hormones called adipokines (eg. leptin and resistin) and 
inflammatory cytokines89.  
One of the major physiological changes that occurs with aging is the redistribution of adipose 
tissue with the subcutaneous depot being reduced and the visceral depot being enlarged in 
humans89. As previously mentioned, HGPS patients suffer from lipodystrophy, characterized 
by a complete loss of subcutaneous adipose tissue. Several studies have found that progerin 
or prelamin A accumulation impairs the differentiation into mature adipocytes in vitro, the 
cells being unable to commit to the terminal differentiation stage90-93. Another interesting study 
further confirmed those observations and characterized the adipose tissue of progerin-
expressing mice, concluding on lipodystrophic mice with increased mitochondrial biogenesis 
and energy expenditure94. However, how progerin expression can lead to adipose tissue 
depletion in vivo and the mechanisms underlying such phenomenon remain little 
investigated. 
The arteries 
Arteries are part of the cardiovascular system, which consists of the heart, blood and blood 
vessels. Like the adipose tissue, arteries stem from the mesoderm during embryonic 
development. They include a blood vessel wall that can be decomposed into three specific 
layers: the tunica intima, the tunica media and the tunica adventitia. Each layer is made up of 
different cell types conferring various roles to the tissue.  
The tunica intima corresponds to the innermost layer of the artery that is in direct contact 
with the blood, and is composed of a thin sheet of ECs embedded in the basal lamina. In that 
setup, endothelial cells play a structural role, giving their shape to arteries. The tunica media 
that is sandwiched between the tunica intima and tunica adventitia, consists of elastic tissue 
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and vascular smooth muscle cells (VSMCs) able to contract and to provide shear strength. 
The tunica adventitia, on the other hand, is the outermost layer of the arteries and is mostly 
formed by collagen and fibroblasts. Arteries are known to participate in the respiration of 
tissues by transporting oxygenated blood from the heart.  
During aging, arteries encounter structural and functional changes with the development of 
arteriosclerosis and the loss of distensibility95. In HGPS, patients present an atherosclerotic 
phenotype characterized by a thickened intimal layer, calcification and loss of VSMCs in the 
media, acute fibrosis in the adventitia, indications of plaque erosion and/or rupture and 
inflammation96. The vascular pathology is of particular interest in the HGPS field, as 
cardiovascular disease is considered as the predominant cause of death in affected children. 
In an in vitro experimentation, Zhang et al. demonstrated a critical role of PARP1 in smooth 
muscle cell death, therefore suggesting its involvement in the loss of VSMCs associated with 
HGPS70. To further comprehend the underlying cause of such vascular alterations, several 
animal models were developed, partially replicating the cardiovascular phenotype observed 
in affected children73,81,97-99. Progerin expression was thus found associated with reduced 
extracellular accumulation of pyrophosphate potentially contributing to vascular 
calcification100. Further investigation of the role of progerin in atherosclerosis revealed that it 
induces endoplasmic reticulum stress in VSMCs101. However, cell type-specific expression of 
progerin implied that ECs and VSMCs are independently able to contribute to cardiovascular 
pathology98,99. Altogether, this suggests that all the mechanistic links are not yet elucidated and 
so, additional research is needed to explore how progerin expression in arteries contributes 
to the tissue decline leading to premature death in HGPS patients. 
The skin 
The skin belongs to the integumentary system, which covers the body and acts as a 
thermoregulator and protector against environmental threats. It emerges from both 
ectodermal and mesodermal germ layers and develops into three main layers: the 
hypodermis, the dermis and the epidermis. The hypodermis is the innermost layer of the 
organ composed mostly of adipose tissue. It exerts metabolic functions, which comprise for 
instance the storage of lipids and the synthesis of vitamin D. Overlying the hypodermis is the 
thick hypervascular dermal layer composed of connective tissue, which harbors many 
sensory receptors conferring a sensation function. The most external layer is then the 
epidermis, which mostly consists of keratinocytes, surrounded by a few melanocytes, 
Langherans cells and Merkel cells. This keratinized layer is in direct contact with the external 
environment and thus serves its role as a protective barrier against pathogens, mechanical 
and chemical damage and dehydration.  
In mice, the epidermal layer is usually thin compared to humans (<25µm compared to >50µm 
in thickness, respectively). It is subdivided into four main layers representing “the circle of 
life of keratinocytes”. The stratum basale (a.k.a. basal layer) is the lower layer in which 
keratinocytes are continuously renewing by a series of cell divisions. Newly formed daughter 
cells then migrate to the next epidermal layer, the stratum spinosum (a.k.a. spinous layer) 
where they lose their proliferative capacity in favor of differentiation. At this stage, 
  13 
keratinocytes start to cornify and produce keratins. As cells continue their ascension towards 
the upper epidermal layers, they reach the stratum granulosum (a.k.a. granular layer) where 
they become more cornified and eventually activate programmed cell death. Finally, dead 
keratinocytes are stacked into several layers forming the stratum corneum (a.k.a. horny layer) 
and end up shedding as newly dead cells come in replacement102.  
The process of cell division occurring in the skin is of great importance as it governs tissue 
homeostasis. Stem cells have the ability to self-renew – i.e. symmetric cell division – but also 
to generate daughter cells committed to differentiation – i.e. asymmetric cell division. Such 
processes can take place via two alternative mechanisms: intrinsic or extrinsic. In intrinsic 
division, preferential apportioning of regulators of cell fate determinant such as ubiquitin is 
crucial, while in extrinsic division contact with the stem cell niche defines the potential to self-
renew103. In the case of skin, extrinsic division can be observed based on the orientation of 
the cell division towards the basement membrane: parallel division indicating symmetric cell 
division; perpendicular division indicating asymmetric cell division104. In HGPS, skin is the 
first organ affected. Investigation of the skin phenotype has revealed that post-natal 
expression of the progeria mutation under the control of the keratin 5 promoter in mice 
results in early loss of epidermal stem cells67. On the other hand, embryonic expression of the 
progeria mutation leads to severe skin abnormalities characteristic of halted development105. 
These phenotypes of depletion of the stem cell pool and arrested skin development are 
suggestive of impaired homeostasis and could be evidence of defects in extrinsic cell division 
caused by progerin expression. 
 Treatment approaches for HGPS 
In the years that followed the discovery of the gene responsible for HGPS, potential 
treatments rapidly emerged. The first one, a farnesyltransferase inhibitor (FTI) called 
Lonafarnib, was found to improve the disease phenotype both in vitro and in vivo by 
inhibiting the farnesylation of prelamin A106-111. Following these promising results, a clinical 
trial was started and children were found to have increased body weight, improved bone 
structure and/or improved vascular stiffness. This treatment resulted in a significantly lower 
mortality rate, characterized by a mean survival increase of 1.6 years75,112,113. The first 
treatment for progeria was thus discovered. Presently, about 30 different treatment strategies 
have been suggested, targeting a wide range of mechanisms, and researchers continue to find 
novel approaches to counteract the deleterious effects of progerin (Figure 7)78,114.  
Reshaping the prelamin A processing  
Although FTI treatment appeared to be a good candidate, it was later suggested that progerin 
may still be prenylated via an alternative pathway: geranylgeranylation. This study described 
that inhibiting both the addition of a farnesyl group and of a geranyl-geranyl group to prelamin 
A’s CAAX motif resulted in a greater accumulation of the protein. In addition, they showed 
that reducing prenylation with a combination of aminobisphosphonates (Zoledronate) and 
statins (Pravastatin) ameliorated HGPS cells defects and improved both health- and lifespan of 
a progeroid mouse model (Figure 7)115. Similarly, the use of mono-aminopyrimidines (Mono-
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AP) resulted in improved cellular phenotypes in HGPS-derived induced pluripotent stem 
cells, acting as both FTIs and bisphosphonates116. But prelamin A carboxymethylation is also a 
key process in the toxicity of progerin, and indeed, it was demonstrated that ICMT inhibition 
by short hairpin RNAs (shICMT) promoted the rescue of senescence and proliferation in 
vitro, as well as a better health- and lifespan in vivo117. 
 
Figure 7. Targeting mechanisms of HGPS by candidate treatment strategies. A wide spectrum of 
treatments for HGPS have emerged since the discovery of the mutation. Treatments aim at 
targeting various characteristic defects of HGPS including the prelamin A processing, downstream 
mechanisms affected by progerin expression (such as the progerin/lamin A interaction, 
mitochondrial biogenesis, inflammation, telomere dysfunction or cellular reprogramming), but also 
autophagy, the splicing machinery or the mutation-causing disease. 
Targeting cellular & molecular abnormalities 
Several other approaches were established to correct the cellular and molecular 
abnormalities induced by progerin expression. Hence, researchers have tried to block 
progerin interaction with lamin A/C, as it accounts for nuclear deformations. Inhibiting such 
linkage by the use of a chemical compound, JH4, was shown to not only improve the nuclear 
morphology in vitro, but also to partly rescue HGPS-related defects and prevent early death in 
a systemic knock-in mouse model of HGPS118. Other studies focused on targeting the 
downstream effectors of progerin. Thus, drugs such as the NRF2-activating drug, the NAT10-
inhibitor Remodelin, the antioxidant Resveratrol targeting SIRT1 or simple supplementations 
of nitrites to increase nitric oxide bioavailability, or of vitamin D to counteract the vitamin D 
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receptor deficiency, were found beneficial to the HGPS phenotype both in vitro and in vivo119-
124. Furthermore, introducing human telomerase mRNA (hTERT) in HGPS cells resulted in 
short telomeres extension together with improved cellular capacities, while reducing NF-κB-
driven inflammation with sodium salicylate hindered premature aging phenotypes in two 
distinct HGPS mouse models (Figure 7)66,125. Many other drugs were found to improve the 
HGPS phenotype likewise. By the means of NAC (N-acetylcysteine), methylene blue, 
metformin, ROCK (rho-associated protein kinase) inhibitors or PPi (inorganic 
pyrophosphate), mitochondrial biogenesis was reinforced by restraining its dysfunction, thus 
regulating various cellular flaws, including reduced ROS levels, DNA damage, senescence and 
progerin expression100,126-130. Finally, cellular reprogramming was investigated as a way to 
promote tissue regeneration. Treatments of HGPS mice with inhibitors of the reprogramming 
repressor DOT1L or by short-term cyclic induction of the Yamanaka factors OSKM (Oct4, 
Sox2, Klf4 and c-Myc) both ameliorated the premature aging defects and extended the lifespan 
(Figure 7)131,132. 
Autophagy activation 
Autophagy is the natural process occurring in cells allowing for the degradation and recycling 
of cellular components, and for which the discovery of related mechanisms led to the award 
of the Nobel Prize in Physiology or Medicine to the researcher Yoshinori Ohsumi in 2016. One 
of the first treatment approaches of HGPS shown to target progerin turnover was using 
rapamycin, an inhibitor of mTOR. This strategy allowed for the autophagy-mediated clearance 
of progerin in vitro, resulting in reduced nuclear blebbings and senescence levels (Figure 
7)133. Further in vitro studies using the rapamycin analog Temsirolimus, the antioxidant drug 
Sulforaphane or all-trans retinoic acids, showed similar advantageous effects134-136. 
Additionally, the proteasome inhibitor MG132 was found to participate in progerin 
degradation partially mediated by autophagy, as well as indirectly reducing prelamin A 
aberrant splicing, resulting in the amelioration of the HGPS cellular phenotype (Figure 7)137. 
Gene therapy 
Nevertheless, a compound- or drug-based therapy may not be sufficient to cure HGPS. HGPS 
would likely require gene therapy to some extent to eliminate the high production of 
progerin. Hence, antisense oligonucleotides-based therapies have previously been tested. 
Morpholinos directed against the lamin A splice donor site or against the aberrant exon 11 
and exon 12 junction, were found efficient, considerably reducing progerin levels in HGPS cell 
lines or mouse model73,138. With the use of the current genome editing technologies, two 
independent laboratories recently published interesting studies back-to-back. In their 
CRISPR/Cas9-based therapy strategies, they targeted the LMNA exon 11 upstream of the HGPS 
mutation of HGPS mice, thus preventing lamin A/progerin production and solely resulting in 
the production of lamin C. These methods markedly reduced progerin expression in vivo, 
which led to improved phenotypes and extended lifespan (Figure 7)139,140. However, one could 
be concerned by the off-target events that may arise with such editing and further 
developments are required to reduce off-target effects before these approaches could be 
ready for patients. 
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HGPS clinical trials 
As mentioned previously, there had been a clinical trial using FTIs in progeria patients75,112. 
Based on the positive outcomes of this first monotherapy and of the studies using statins and 
bisphosphonates, another one rapidly followed. The second clinical trial added Pravastatin 
and Zoledronate to the FTI treatment. However, only the bone mineral density improved and 
the number of patients presenting extraskeletal calcifications and arterial plaques 
considerably increased141. Interestingly, an in vitro study from Capell and colleagues prior to 
the study showing beneficial effects from the combination of such drugs, inferred that 
progerin was not prenylated by any other processes than farnesylation106. This suggests that 
the combination of these drugs may not be suitable to treat HGPS patients. Nowadays, a third 
clinical trial is ongoing, for which phase two was initiated back in 2017. This trial enrolled 60 
HGPS children, who are currently receiving a combination of Lonafarnib and Everolimus, a 
rapamycin analog142. 
However, Nature is complex and intricate. Mice and humans are different species, and of all 
the treatment strategies developed and tested on in vitro and in vivo models of HGPS, not all 
of them might be transferrable to patients or provide the same beneficial effects. Nevertheless, 
a thorough assessment of treatments potential side effects or evaluation of the combination of 
multiple treatments in pre-clinical models is crucially needed. In addition, some treatment 
strategies may have contradictory effects in different models, which is why the choice of 
appropriate HGPS models is of critical importance. Several HGPS models were engineered 
(systemic mice or pigs, humanized models or tissue-specific models), which allow for the 
assessment of the true advantages of a given candidate treatment73,81,97,143,144. A non-negligible 
point is that it is worth testing treatments in models that have acquired a phenotype, as 
patients present a developed disease phenotype before treatment is initiated. As the cure or a 
treatment with more significant benefits for HGPS patients has yet to be discovered, research 
is pursuing to try find new therapies that could be of potential interest to HGPS. 
 Age-associated diseases 
Age-associated diseases correspond to a broad range of diseases that may arise as a 
consequence of aging, aging being a prevailing risk factor. Unlike most progeroid syndromes, 
age-related disorders have a high prevalence in the population and it is estimated that over 
75% of human deaths can be imputed to them145. These include various kinds of conditions 
altering the healthspan such as cancers, vascular disorders (e.g. atherosclerosis), bone-
related disorders (e.g. osteoporosis), metabolic disorders (e.g. type 2 diabetes), 
neurodegenerative diseases (e.g. dementia) and urinary system disorders (e.g. chronic 
kidney disease) among others (Table 1)146-149. These pathologies are defined as chronic, 
meaning that they are not genetically inherited and should not be confused with accelerated-
aging disorders. Interestingly, some illnesses like Alzheimer’s disease and Parkinson’s disease 
fall into both the chronic and accelerated categories, as they can be either inherited or 
sporadic. How aging impacts these diseases is generally investigated by counteracting and 
postponing the onset and progression of alterations commonly observed during aging in 
specific disease-affected tissues. 
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Table 1. Overview of age-associated diseases  
BIOLOGICAL SYSTEM 
AFFECTED 
AGING-ASSOCIATED 
DISEASE SHARED HALLMARKS OF AGING 
Nervous system 
Alzheimer's disease 
Mitochondrial dysfunction, loss of 
proteostasis, cellular senescence, altered 
intercellular communication 
Parkinson's disease Cellular senescence, altered intercellular communication 
Circulatory system 
Atherosclerosis Cellular senescence, telomere attrition, genomic instability, epigenetic alterations 
Cardiovascular 
diseases 
Mitochondrial dysfunction, cellular 
senescence, deregulated nutrient sensing, 
stem cell exhaustion 
Respiratroy system Chronic obstructive pulmonray disease 
Mitochondrial dysfunction, loss of 
proteostasis, cellular senescence, altered 
intercellular communication, telomere 
attrition, deregulated nutrient-sensing, 
stem cell exhaustion  
Musculoskeletal 
system 
Sarcopenia Altered intercellular communication 
Osteoporosis Altered intercellular communication 
Osteoarthritis 
Mitochondrial dysfunction, cellular 
senescence, altered intercellular 
communication 
Metabolic system Type-2 diabetes Cellular senescence, genomic instability, deregulated nutrient sensing 
Urinary system Chronic kidney disease 
Cellular senescence, altered intercellular 
communication, deregulated nutrient 
sensing 
All systems Cancer Cellular senescence, altered intercellular communication 
Table derived from Wang & Bennett, 2012; Chiao & Rabinovitch, 2015; Kubben & Misteli, 
2017; Franceschi et al., 2018. 
 An example of age-associated diseases: Chronic kidney disease 
Chronic kidney disease (CKD) is an often-silent disease that affects 10-12% of the global 
population. It is a major health problem and was ranked as the 12th most prevalent cause of 
death, accounting for 1.1 million deaths worldwide150. CKD can be defined by the presence of 
damaged and dysfunctional kidneys, which can threaten health. It is classified as five different 
stages associated with the glomerular filtration rate, which relates to the degree of severity of 
kidney dysfunction151. Thus, CKD is often diagnosed by assessing the glomerular filtration rate, 
along with the serum creatinine and/or the urine albumin excretion. In most cases, CKD 
arises as a consequence of diabetes, hypertension and glomerulonephritis, but it can also be 
idiopathic or due to hereditary diseases such as polycystic kidney disease. As the disease 
progresses, diverse complications indicative of a premature aging process occur including 
anemia, osteoporosis, infections, muscle wasting, dyslipidemia, frailty, neuronal damage and 
cardiovascular disease (CVD)152,153. 
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 CKD & CVD  
CKD may be considered as a clinical example of premature vascular disease. Patients 
suffering from such disease have an increased risk of CVD associated with the disease 
progression. Cardiovascular mortality is regarded as the main cause of death in CKD patients 
undergoing dialysis, and is 10-20 times increased in those patients compared to the general 
population154. CVD pathogenesis in CKD can be attributed to many various risk factors. Hence, 
hypertension is thought of as a traditional risk factor that participates in cardiac damage. 
Indeed, it was suggested to induce left ventricular hypertrophy, along with anemia and low 
glomerular filtration. Coronary ischemia, abnormal mineral metabolism, excess of proteins in 
the urine and inflammation are also associated with CKD-related development of CVD153. 
However, the impact of CKD on the development of CVD is very complex, and all the 
mechanisms leading to the rapid progression of vascular disease in the context of CKD are 
still not entirely established.  
Early vascular aging 
In CKD, an apparent discrepancy between chronological and biological vascular age can be 
observed, thus representing an “accelerated arterial aging” phenotype. This vascular change 
is identified by arterial stiffening and enlargement, increased intima-media thickness and 
fibrotic adventitia155-157. Such damage lead to a lower shear stress (i.e. reduced tangential force 
of the blood on the endothelial layer of the artery), a mechanical force normally promoting 
endothelial cell survival and quiescence158. The arterial distensibility observed in CKD 
represents vascular calcification and is generally associated with mineral and bone 
disorders159,160. Increased calcium content and calcification of the intimal and/or medial layer 
of the vascular wall are common features of CKD arteries, in turn leading to atherosclerosis. 
This phenomenon is essentially induced by circulating uremic toxins, systemic inflammatory 
cytokines and by impaired calcium and phosphate metabolisms in the case or renal 
disease161,162. In addition, VSMCs apoptosis correlates with medial calcification. Since VSMCs 
exhibit phenotypic plasticity, they are hypothesized to contribute to media calcification. 
However, this remains debated in the cardiovascular field163,164. This controversy emphasizes 
the need to further elucidate the underlying mechanisms leading to vascular damage, which 
could be of particular interest to understand and prevent CKD-related CVD. 
 Treatment approaches 
Means of treating CKD are multiple, however, there is no cure and no specific medicines for 
such disease. Yet, new drugs like SGLT2 inhibitors and NRF2 agonists bring hope for better 
treatments of this expanding patient population165. Current treatments aim at reducing 
complications and slowing down or arresting the disease progression by targeting risk factors. 
In the early stages of CKD, a proper lifestyle along with a healthy diet is important. Some 
therapies may include medications controlling the blood pressure or the cholesterol levels, 
whereas others may use drugs treating anemia, relieving oedema or protecting the bones166. In 
end-stage renal disease, when glomerular filtration rate is <5-7 ml/min, renal replacement 
therapy like dialysis or kidney transplantation are needed for survival. Dialysis treatment 
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artificially takes on the function of healthy kidneys, thus removing extra fluid and uremic 
waste products from the blood. Kidney transplantation improves survival markedly, whereas 
the mortality rate in dialysis patients is around 20% (mostly because of CVD) and comparable 
to metastatic cancer disease153. Given the high mortality rate and the important costs of renal 
replacement therapy, alternative treatment strategies are needed. A future treatment 
approach that may fit such requirements concerns the use of regenerative medicine. Indeed, 
restoring the kidney function with the use of stem cell therapy, for example, could be of great 
help to slow the disease progression167,168. However, such treatment is not available yet, and 
researchers are studying the disease mechanisms in search for a suitable therapy for CKD. 
 Aging, HGPS & CKD: what is the link? 
It is becoming more and more evident that lamin A plays a role during physiological aging. 
But despite the fact that HGPS and normal aging share common mechanisms, their connection 
remains hazy. 
 Progerin expression in healthy aging 
What might explain the similitude between HGPS and normal aging is the expression of 
progerin. Indeed, activation of the LMNA cryptic splice site resulted in low progerin 
transcripts levels in skin fibroblasts from healthy aged individuals. Those aged cells presented 
with an accumulation of nuclear abnormalities comparable to HGPS cells, including nuclear 
structure deformation, reduced levels of HP1 and H3K9me3, and increased DNA damage169. 
Interestingly, blocking of the LMNA cryptic splice site in those aged cells resulted in the 
reversibility of the aforementioned nuclear defects169. This discovery was further supported 
by other studies that demonstrated the presence of progerin at the protein level60,170. Progerin 
expression in primary human dermal fibroblasts led to mitotic defects associated with HGPS, 
and altogether, these findings reinforced the idea that HGPS and normal aging may have a 
shared cellular and molecular core60. Indications of progerin expression and accumulation in 
vitro led to the screening of a few tissues from healthy individuals of various ages. Thus, it 
was demonstrated that progerin is indeed produced in distinct skin regions from aged 
individuals. In this study, progerin mRNA levels were established as stable among the 
different tissue samples, whereas the protein was found to accumulate with age170. Additional 
in vitro analysis of unaffected dermal fibroblasts also confirmed the existence of progerin 
transcripts in very small amount and provided evidence for increased progerin mRNA in late-
passage cells171. Similarly, it was suggested that the toxic protein is also present during aging in 
arteries from healthy individuals, and particularly in the adventitial layer. In this case, the 
authors claimed positive detection of progerin-expressing cells as a punctate cytoplasmic 
staining96. As a whole, these data ascertain the presence of progerin in healthy aged cells; still, 
the consequences of progerin production in just a few cells or overall at low levels, on normal 
aging remain unclear and under study. 
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 HGPS to study CKD-related accelerated vascular aging 
One may wonder what links HGPS to CKD. As a starter, both diseases are somewhat related to 
aging, HGPS being a premature aging disorder and CKD being an age-associated disease. But 
most strikingly, they share a common accelerated vascular aging phenotype. Briefly and as 
mentioned earlier, patients can present vessel plaques and vascular stiffness accompanied by 
inflammation in both cases. Vascular damages are characterized by thickened intima, media 
calcification and loss of VSMCs, and fibrotic adventitia (Figure 8).  
 
Figure 8. Shared vascular phenotypes and pathologies between HGPS & CKD. Characteristic 
features of the vascular phenotype and pathology of HGPS patients are similarly reproduced in 
CKD patients.  
Of note, lamin A and prelamin A were previously found associated with vascular calcification 
in nephrectomized rats and VSMCs cultured under calcifying conditions172. Prior to this study, 
the precursor prelamin A was already described as accumulating in vitro and in vivo in 
calcifying human VSMCs173,174. This accumulation was suggested to partake in persistent DNA 
damage, by inhibiting DDR activation, thereby promoting VSMCs osteogenic differentiation 
and activating senescence and the SASP, in turn contributing to vascular calcification173,175,176. 
Besides, progerin was found expressed in arteries from healthy aged individuals, its 
expression increasing with aging96. More recently, arterial stiffness and plaque formation were 
associated with progerin-expressing VSMCs in mice, and endoplasmic reticulum stress was 
proposed as an underlying mechanism of atherosclerosis98,101,120. Altogether, these reports 
imply a possible role for progerin in accelerated vascular aging. The resemblance in the 
vasculatures of HGPS and CKD patients indicates that perhaps progerin is expressed in CKD 
arteries and might contribute to tissue pathology. 
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2. AIMS OF THE THESIS 
This thesis aims at increasing the current understanding of the cellular and molecular 
mechanisms underlying progerin expression in the context of HGPS and more common age-
associated diseases, in order to develop potential therapeutic strategies. 
The specific aims were: 
Paper I 
• To understand how progerin accumulation results in depletion of the adult stem cell 
population and impaired tissue homeostasis. 
Paper II 
• To analyze whether expression of progerin in a low frequency of cells of the 
adipose tissue contributes to tissue pathology during physiological aging. 
Paper III 
• To analyze whether the progerin protein contributes to CKD-related accelerated 
vascular aging, and if present, to determine the cause for its expression. 
Paper IV 
• To investigate whether telomere dysfunction in HGPS results in the accumulation of 
telomeric non-coding RNAs. 
• To evaluate the potential of telomeric sequence-specific antisense oligonucleotides 
as a novel treatment strategy for HGPS. 
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3. RESEARCH APPROACH 
 In vitro models of HGPS 
In vitro systems are useful to answer biological questions, and for instance, they can be used 
to study the effect of a protein overexpression or silencing, but also to assess various 
treatment strategies. Several in vitro models of HGPS were used throughout the different 
papers.  
Both papers I and IV used primary human dermal fibroblasts from HGPS patients and 
controls. These fibroblasts are a widely used model in progeria research given their 
physiologically relevant expression of progerin. In our case, HGPS patients cells were 
manipulated to better grasp the mechanisms underlying progerin-associated disrupted tissue 
homeostasis and telomere dysfunction. Paper II employed the 3T3-L1 cell line, which is 
derived from murine 3T3 cells. These cells are commonly used in the adipose tissue biology 
research field, as they are capable of differentiating into cells phenotypically resembling 
adipocytes. In our experimental setup, 3T3-L1 cells were transfected with various expression 
vectors, thus overexpressing lamin A, progerin or both in order to understand the 
contributions of either of these proteins to preadipocytes proliferation and differentiation. 
Finally, paper IV utilized human skin fibroblasts (BJ cell line) constitutively overexpressing 
lamin A and progerin, and doxycycline-inducible normal dermal fibroblasts that allowed for 
a tunable expression of progerin and lamin A in a dose-dependent manner. These particular 
cell models were used to further assess progerin-associated telomere dysfunction. Of note, 
we also manipulated an in vitro system in paper III. Human-derived primary aortic vascular 
smooth muscle cells were grown and supplemented with uremic serum to mimic a CKD 
environment and determine whether the c.1824C>T mutation could be induced by uremic 
surroundings.  
Despite being very useful organic tools, in vitro models are not complex enough systems to 
entirely reflect the biology of living organisms, as they do not take into account the systemic 
environment. Some regulatory mechanisms occurring via paracrine and/or endocrine 
signaling cannot take place in Petri dishes; therefore in vivo animal models are important 
complements to in vitro systems. 
 Mouse models of HGPS 
 Conditional mouse models  
In order to study HGPS and aging, our laboratory developed several mouse models based 
on a tetracycline-inducible system: the Tet-Off system80,143,144. The Tet-Off system is a binary 
transgenic system that consists of a target gene downstream of a tetracycline responsive 
promoter element (tetop), and a transactivator (tTA) downstream of a tissue-specific 
promoter. This conditional model allows for the control of transgenic expression temporally 
by adding doxycycline, a tetracycline derivative, and spatially with the use of a tissue-
specific promoter (Figure 9).  
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Thus, this kind of system not only gives the possibility to study transgenic expression in a 
given tissue, but also gives the chance to study the possibility of disease reversal by 
silencing the protein expression after the appearance and progression of a phenotype.  
 
Figure 9. Conditional HGPS mice based on the Tet-Off system. In the Tet-Off system, 
transcription of the target gene is regulated by the administration of doxycycline (Dox). In the 
absence of doxycycline, proteins are encoded by the transactivator (tTA), which is under the 
control of a tissue-specific promoter (here: NSE promoter), and will bind to the tetracycline 
responsive promoter element (tetop) located upstream of a target gene (here: human LMNA 
minigene), thus inducing its transcription. The LMNA minigene contains the coding regions of 
lamin A and the 1824C>T mutation. Its transcription results in the synthesis of the human 
lamin A, human progerin and GFP proteins.  
In our mouse systems, the target gene corresponds to a human LMNA minigene, which 
consists of exons 1-11, intron 11 and exon 12. Exon 11 carries the most common HGPS 
mutation (LMNA c.1824C>T, p.G608G). This minigene allows for the production of both 
human lamin A and progerin, which is more physiologically relevant since the mutation is 
present in the heterozygous form in HGPS patients and does not create a perfect splice site 
(meaning that progerin is not always spliced from the mutant allele). This sequence is 
followed by an internal ribosomal entry site (IRES), allowing for the independent translation 
of enhanced green fluorescent protein (eGFP) located downstream of the IRES. At its end, 
the minigene includes a SV40/polyA tail facilitating mRNA stability and translation (Figure 9). 
The transactivators that were used in this thesis are the keratin 5-mediated transactivator 
(K5-tTA) for specific transgenic expression in the skin (Paper I and IV)143,177, and the neuron-
specific enolase-mediated transactivator (NSE-tTA) for transgenic expression mainly in the 
brain but also sparsely in the adipose tissue (Paper II) (Figure 9)80,178. Together these mouse 
models allowed for the investigation of the underlying mechanisms of progerin expression 
and the experimentation of a new treatment strategy. 
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 Knock-in and transgenic mouse models  
Several systemic mouse models have been developed to study HGPS, including:  
• LmnaHG/+: knock-in mice solely expressing progerin from one of the Lmna allele and lamin 
A/C from the other allele. These mice recapitulate symptoms of HGPS such as bone 
alterations, loss of subcutaneous fat and premature death, however, they display no signs 
of atherosclerosis179. 
• BAC G608G: mice overexpressing human lamin A and progerin. Single-copy BAC mice 
only display a vascular phenotype resembling the one observed in HGPS patients, 
without alteration of the life expectancy81. 
• Zmspte24-/-: mice accumulating farnesylated prelamin A and presenting many phenotypic 
features of HGPS including skeletal abnormalities, progressive hair loss, muscle weakness 
and premature death180. Of note, deletion of ZMPSTE24 likely affects other proteins as 
well, in addition to prelamin A. 
However, the most widely used model nowadays is the LmnaG609G knock-in mouse model as 
these mice ubiquitously express progerin and phenocopy most clinical manifestations of 
HGPS. This mouse strain was generated by replacing the wild-type mouse Lmna gene by a 
mutated allele carrying the c.1827C>T; p.Gly609Gly mutation73. This mutation is the murine 
equivalent of the human HGPS c.1824C>T; p.Gly608Gly mutation. Heterozygous mice 
(LmnaG609G/+) display a milder phenotype than homozygous mice (LmnaG609G/G609G) due to a 
slower progression of the disease. LmnaG609G/G609G mice rapidly develop pronounced 
phenotypic features resembling those of HGPS patients, including growth retardation, 
abnormal bone structure, loss of adipose tissue, cardiovascular defects and premature 
death73. Homozygous LmnaG609G mice were used in a competitive transplantation experiment 
in paper III. 
 From mouse to human  
Mouse models are complex living organisms useful to study the basis of aging, which 
mechanisms may be conserved among different species. However, human specimens are 
central actors in the current medical and scientific advancements. 
In paper II, we employed subcutaneous adipose tissue biopsies originating from healthy 
kidney donors undergoing surgery in order to determine progerin expression levels, while in 
paper III, we used human blood and arterial tissue biopsies to investigate CKD-related 
accelerated vascular aging. Epigastric arteries were obtained from CKD stage 5 patients (i.e. 
with severe kidney dysfunction) undergoing living-donor renal transplantation. Given the 
difficulty of the procedure, control arteries were instead obtained from individuals 
undergoing gallbladder removal or inguinal hernia surgery. To be considered as controls, 
these individuals had to present no history of cardiovascular disease.  
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The human population is highly heterogeneous, and there are a number of confounding 
factors that may influence the research data. Our sample set was composed of both male 
and female patients from various ages with different causes for disease onset and 
progression, and receiving diverse treatment options. 
 How to study HGPS & age-associated disorders?  
There are no particular methods to study HGPS and age-associated diseases. In this thesis, 
bright-field and confocal microscopy are the primary tools used, as they were suited for 
pathological examination, and spatial analysis and quantification of proteins and transcripts 
within specific regions of a tissue. Hence, molecular biology techniques including 
immunohistochemistry, in situ hybridization and immunofluorescence were broadly used 
first and foremost to appreciate progerin expression, but also to visualize specific aging-
associated defects such as DNA damage, senescence, inflammation or telomere dysfunction. 
One of the major advantages of immunostainings is the possibility of multiplexing, i.e. to 
combine several antibodies to detect multiple proteins at once. However, co-stainings are 
limited by the antibodies host species and in the case of tissue immunofluorescence, by the 
number of microscope lasers used to excite the secondary antibodies fluorophores. That is 
the reason why, in some cases, FACS sorting was performed to look at gene or protein 
expression in specific cell types. In other instances, protein detection by an antibody was 
not sensitive enough, and other methods targeting DNA or mRNA were preferred. Thus, 
progerin expression in human tissues or SASP levels were occasionally detected by droplet 
digital PCR (ddPCR) or quantitative RT-PCR. In the same manner, to get a better 
understanding of pathways affected by progerin expression, RNA sequencing methods, 
expression arrays and bioinformatics analysis were applied.  
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4. RESULTS & DISCUSSION 
 Paper I. Accumulation of progerin affects the symmetry of cell division 
and is associated with impaired Wnt signaling and the mislocalization 
of nuclear envelope proteins. 
Accumulation of progerin is known to ultimately result in tissue dysfunction. However, how 
cellular and molecular defects contribute to the disruption of tissue homeostasis remains 
unclear. In an attempt to elucidate such mechanisms, we hypothesized that the symmetry of 
stem cell division is altered, thus participating in the impaired tissue growth and renewal 
generally observed in progeria-like conditions (Figure 10).  
 
Figure 10. Graphical abstract of Paper I. Examination of postnatal day 4 HGPS mouse skin 
revealed defects in cell division, characterized by an increase in symmetric cell division and 
proliferation compared to wild-type mice. Associated with the mislocalization of the nuclear 
envelope proteins emerin and nesprin-2, the Wnt/β-catenin signaling pathway was found 
disrupted, which argued for its potential involvement in the observed aberrant cell division 
process in HGPS. 
Study design 
In this study, we took advantage of a conditional HGPS mouse model, defined by tissue-
specific expression of the most common HGPS mutation (LMNA c.1824C>T) and leading to 
halted skin development105. Skin samples were collected at embryonic day 18.5 (E18.5) and 
postnatal day 4 (PD4) from both HGPS and littermate control mice, in order to assess the 
symmetry of stem cell division with progressive accumulation of progerin. The epidermal 
stem cell population was characterized by transcriptomics, and affected pathways such as 
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proliferation and Wnt signaling were further validated, either in vivo or in patient and control 
fibroblasts. Levels of associated NE proteins were likewise assessed to try to get a global 
explanation of the processes leading to impaired skin homeostasis. 
Progerin accumulation favors symmetric cell division 
It has previously been demonstrated that asymmetric cell division promotes stratification 
and differentiation of mammalian skin, thus generating both the basal and suprabasal layers 
during development104. Since our HGPS mice present epidermal hyperplasia, we first 
assessed the symmetry of cell division of basal epidermal stem cells. Immunofluorescence of 
the mitotic spindles revealed that as progerin accumulated from E18.5 to PD4 in HGPS skin, 
up to 66.7% of epidermal stem cells underwent symmetric division, whereas wild-type skin 
showed a similar distribution of asymmetric vs. symmetric cell divisions. These in vivo data 
are in accordance with previous in vitro results, where progerin overexpression in neural 
stem cells led to increased intrinsic symmetric cell division181. Our data suggest that 
keratinocytes present an aberrant cell division process contributing to the impaired 
homeostasis observed in these HGPS mice. 
Impaired stem cell function in HGPS skin 
Since the symmetry of cell division relies on the ability of stem cells to divide, we next 
investigated stem cell impairment primarily in the basal layer of PD4 mice epidermis by RNA 
sequencing. A total of 308 genes were found to display a significant change in gene 
expression between HGPS and wild-type keratinocytes. In agreement with the observed 
phenotype, gene ontology analysis revealed that processes such as epidermal development 
or regulation of cell differentiation were affected. We then applied previously described gene 
expression patterns to our sequencing dataset in order to determine which particular 
lineages of proliferative keratinocytes were affected. Indeed, there have been more than one 
type of stem/progenitor cells described in the skin, and several models have emerged, 
attempting to explain epidermal maintenance182-185. However, these are still debated. 
Nevertheless, following the two stem-cell population model based on label-retaining cells 
(LRCs) and non-LRCs185, we found expression patterns associated with LRCs to be especially 
downregulated in HGPS interfollicular epidermis. Similarly, expression patterns of hair 
follicle stem cells and transit-amplifying stem cells were also downregulated in HGPS hair 
follicles183. These apparent gene expression repressions were further validated by 
expression array and in situ hybridization against keratin 15, a marker of hair follicle stem 
cells. Interestingly, keratin 15 was previously shown to be associated with non-homeostatic 
and hyperproliferative conditions186-188. Transcriptomic analysis of genes associated with 
quiescence and proliferation suggested a more proliferative state in HGPS keratinocytes 
compared to wild-types. Similarly, at the protein level, HGPS skin presented an increased 
frequency of cells positive for the mitotic marker PHH3. But the balance between 
proliferation and differentiation is essential in skin homeostasis, and therefore, we 
considered expression changes in epigenetic modifiers responsible for the regulation of 
stemness and cell-commitment genes. Our data revealed that the epigenetic 
proliferation/differentiation switch was not affected by progerin accumulation in our 
progeroid mouse model, as supported by another study where markers of epidermal 
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terminal differentiation were found expressed in these same mice105. However, this appears 
to be in contradiction with previous data from Shumaker et al., which indicated that the 
epigenetic mark EZH2, a known regulator of keratinocytes proliferation and differentiation, 
was downregulated in HGPS patient cells30,189. Nevertheless, our data suggest that stem cells 
are dysfunctional and favor proliferation under progerin expression, likely resulting in 
disrupted skin homeostasis.  
Altered Wnt/β-catenin signaling pathway in HGPS 
To uncover the underlying pathway responsible for the shift in symmetric cell division in 
HGPS skin, we analyzed our RNA sequencing data using Wikipathway. This indicated the 
Wingless/Integrated (Wnt) signaling as being the most significantly affected pathway in 
progerin-expressing keratinocytes. In comparison to Notch and Hedgehog signaling 
pathways, which together with Wnt, are involved in the proper maintenance of stem cell 
equilibrium in the skin, Wnt appeared as the most significantly downregulated pathway in 
HGPS basal keratinocytes. Wnt signaling has been characterized as both canonical and non-
canonical pathways, and more importantly, the canonical Wnt/β-catenin pathway was 
previously associated with the regulation of epidermal stem cell renewal190. We found this 
pathway to be affected in both patient fibroblasts and PD4 HGPS skin, with nuclear β-catenin 
levels being diminished compared to controls. We attempted a rescue experiment, in which 
Wnt3a was supplemented to patient and control fibroblasts over a 24-hour time course. 
Nuclear β-catenin was found to increase over time as measured by Western blot and 
immunofluorescence, and the expression levels of the Wnt target gene Axin2 were likewise 
increased after stimulation. Despite the positive effect of such in vitro treatment, both β-
catenin and Axin2 levels remained lower in HGPS compared to control cells. Of note, low 
Wnt signaling has been associated with symmetric cell division in developing hair follicles, 
thus underlining its plausible involvement in the phenotype observed in our progeroid 
mice191. 
NE proteins mislocalization in progerin-expressing cells 
β-catenin reduction could potentially be explained by altered nuclear transportation. Indeed, 
the NE protein emerin was suggested to be involved in β-catenin exportation from the 
nucleus192, and we found emerin levels to be significantly increased in our HGPS mice 
keratinocytes at PD4, thus suggestive of a more active exportation. But emerin is a direct 
interactor of lamin A, and to exclude the possibility that its accumulation at the nuclear rim 
results from the overexpression of both progerin and lamin A, we analyzed its levels in the 
skin of mice overexpressing lamin A only. The fact that emerin levels were similar to that 
observed in wild-type mice suggested that its accumulation was a direct consequence of 
progerin expression. In addition, the LINC complex protein nesprin-2 was also found to be 
important for the nuclear translocation of β-catenin193. Interestingly, nesprin-2 levels were 
significantly reduced at the nuclear periphery in HGPS patients cells. This is in agreement 
with a previous report from Arsenovic and colleagues194. This phenomenon could potentially 
be explained by progerin interaction with SUN1, the direct binding partner of nesprin-2, 
which was found to result in SUN1 aggregation51,195,196. Since the diffusion of nesprins was 
observed upon the disruption of the SUN1-nesprin interaction, it could be inferred that the 
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interaction between progerin and SUN1 reduces the binding affinity of SUN1 for nesprin-2, 
thus resulting in nesprin-2 mislocalization51. Altogether, our results combined with previous 
studies suggest that the observed nuclear loss of β-catenin in progeroid keratinocytes and 
fibroblasts may be the outcome of overactive exportation of β-catenin by emerin or inert 
translocation by nesprin-2. It is worth noting that a previous report showed that 
overexpression of nesprin-2 benefitted HGPS mice197. Furthermore, it is acknowledged that 
changes in the NE during cell division greatly contribute to the control of cell cycle 
progression198, and it could therefore be hypothesized that the NE remodeling occurring with 
progerin expression may impact the proliferative state of cells. Emerin and nesprin-2 were 
found otherwise implicated in cell polarity, further supporting a role for these proteins in cell 
division and migration, and implying their contribution to the extensive symmetric cell 
division detected in HGPS keratinocytes199-201. 
 Paper II. Rare progerin-expressing preadipocytes and adipocytes 
contribute to tissue depletion over time 
Progerin expression in an entire cell population leads to tissue damage, but can a small 
fraction of progerin-accumulating cells contribute to tissue pathology? Progerin has been 
found in various occasions in cells and tissues from healthy aged individuals, but the 
significance of such findings is still contested given its rare occurrence in few cells of the 
tissues and that it was found very lowly expressed. It would be meaningful to understand 
whether progerin is actually involved in the tissue degradation that occurs with aging, and if 
its rare expression contributes to the progression of aging-associated diseases (Figure 11). In 
fact, this would unveil whether progerin could be used as a tool to understand mechanisms 
that drive physiological aging, and whether it could be an appropriate treatment target to 
slow the progression of age-related tissue decline. 
 
Figure 11. Graphical abstract of Paper II. Analysis of subcutaneous white adipose tissue in aging 
transgenic mice showed a sustained low frequency of progerin-expressing cells. This was 
associated with the apparition of age-associated defects including abnormal proliferation, 
increased DNA damage and senescence, and systemic inflammation, suggesting that even when 
present in a small fraction of cells, progerin is able to contribute to tissue pathology over time. 
Interestingly, progerin was also found at low transcript levels in human subcutaneous fat.  
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Study design 
In this study, subcutaneous adipose tissues were collected from healthy human individuals 
(age range: 31-66 years) to evaluate the presence of progerin at the RNA level. Subsequently, 
we used a humanized progeroid mouse model engineered to express both lamin A and 
progerin under the control of the enolase promoter, which results in expression of the 
mutation in several tissues including the brain, skin, bone, heart and the adipose tissue80,202. 
These mice were referred to as rare progerin-expressing (RPE) mice. Previous gross 
examination of these mice revealed reduced body weights and fat depletion at 90 weeks of 
age80. Various organs were collected from 30-, 60- and 90-week-old RPE and control mice. 
Hypothalami and brainstem were used to assess progerin expression and pathological 
events, including apoptosis, and astrocytes and microglia activation. Inguinal subcutaneous 
white adipose tissues (sWAT) were collected for determination of cell type-specific progerin 
expression and phenotypical evidence of tissue damage such as aberrant proliferation, 
increased DNA damage, senescence, cell death and macrophage infiltration. Ectopic fat 
deposition was evaluated in the heart, liver and skeletal muscle from RPE and control mice, 
and sera were collected for measures of metabolic disturbances and systemic inflammation. 
In vitro systems were generated to further assess the detrimental characteristics of progerin 
expression, including proliferation and differentiation capacity of progenitor cells.  
Low levels of progerin in healthy human sWAT 
Since progerin was previously found in apparently healthy human aged cells, skin and 
arteries60,96,169-171, we thought to investigate whether it could also be found in human adipose 
tissue. Analysis of lamin A and progerin transcripts revealed that there were about 2.26 
copies of the progerin transcript per 1000 copies of the lamin A transcript. This ratio of 
progerin to lamin A transcripts was 114.77-fold lower than that of a HGPS patient dermal 
fibroblasts. Such low transcript levels of progerin could not be detected at the protein level 
by immunostaining, probably because of the sensitivity of the antibody. 
Adipose tissue depletion with aging in RPE mice 
As our RPE mice were previously found to display a loss of subcutaneous adipose tissue80, 
we then investigated whether other fat depots were affected. We found that among the 
epididymal and interscapular brown adipose tissues, the RPE subcutaneous white adipose 
tissue was the most affected with aging, its proportions in 90-week-old mice being 
significantly smaller than that of age-matched controls and of 60-week-old RPE mice. 
Scanning electron microscopy revealed that 90-week-old RPE sWAT exhibited mild fibrosis 
and occasional loss of adipocytes in addition to smaller adipocytes compared to control 
sWAT as revealed by histological analysis, all of which inferred functional impairment of the 
tissue203. We then assessed metabolic alterations by first considering ectopic fat deposition. 
However, the heart, liver and muscle from 90-week-old RPE mice did not display abnormal 
fatty acid storage. Likewise, circulating leptin levels did not significantly differ between RPE 
and control mice, suggesting that sWAT metabolism was not severely disrupted despite 
presenting several pathological anomalies. 
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No involvement of the hypothalamus and brainstem in RPE mice fat depletion 
Hypothalamic and brainstem neurons play a role in fat metabolism by sensing peripheral 
metabolic signals. They are able to control fatty acid metabolism and energy homeostasis via 
the autonomic nervous system and particularly the sympathetic fibers, which innervate the 
white adipose tissue204,205. Hence, given the model we were experimenting on, we studied the 
hypothalamus and to some extent the brainstem, in order to determine whether they were 
contributing to the sWAT loss observed in our RPE mice (Figure 12).  
 
Figure 12. No overt microglial activation. Representative immunofluorescent staining pictures of 
wild-type and HGPS mice depicting microglial states (green, left: example of resting microglia, 
right: example of activated microglia). Analysis revealed no particular activation of microglia in the 
brainstem of 90-week-old HGPS mice compared to wild-types. 
Progerin was not found expressed in neurons composing the hypothalamus of 60-week-old 
mice and pathological analysis did not reveal signs of satellitosis. Further examination by 
immunostainings did not show evidence of aberrant caspase 3-mediated apoptosis, nor of 
astrocytes activation in RPE mice compared to wild-type. Similarly, in 90-week-old 
brainstems, IBA1 staining showed comparable frequencies of activated microglia between 
RPE and control mice (Figure 12). Altogether, these findings suggested that central nervous 
system defects were not directly accountable for the observed loss of sWAT in our RPE 
mice.  
Rare progerin-expressing preadipocytes and adipocytes 
The central nervous system being apparently uninvolved in the observed sWAT loss, we 
then investigated potential mechanisms leading to such deficiency focusing on progerin 
expression directly in the sWAT. But first, we tested whether overexpression of lamin A 
contributed to the phenotype. Using a mouse overexpressing human lamin A only under the 
control of the enolase promoter, we found that the body weights, as well as the hypodermal 
adipose layer, were not affected in aged mice suggesting that progerin might be responsible 
for sWAT depletion in our RPE mice. Detection of human lamin A indicated a low frequency 
and distribution of the protein in the lamin A overexpressing mice skin. Hence, we 
proceeded to a progerin immunostaining in 30-, 60- and 90-week-old RPE mice, which 
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showed a sustained expression with aging, represented by low frequencies of progerin-
positive cells ranging from 4.4% to 6.7%. The adipose tissue being composed of multiple cell 
types, we isolated the stromal vascular fraction in order to identify which of the major cell 
populations were expressing progerin. We found that only preadipocytes were positive for 
progerin and that they represented less than 1.17% of the total stromal vascular fraction. This 
indicated that the cell populations corresponding to the low frequency of progerin-
expressing cells in RPE sWAT were preadipocytes and mature adipocytes. It should be 
noted that a previous study conducted on mosaic Zmpste24-deficient mice showed that 
accumulation of unprocessed prelamin A in about 40-60% of the cells of multiple organs did 
not lead to pathological alterations or premature death. This suggested that the development 
of prelamin A-induced premature aging most likely result from cell-extrinsic mechanisms83. 
But we decided to test whether progerin is directly involved in the observed sWAT decline, 
and so we next assessed various marks of cellular aging and progeria. 
Increased cellular and molecular defects over time in RPE sWAT 
In human adipose tissue, hyperplasia is negatively correlated with cellular hypertrophy206. 
Adipocytes being smaller in size in RPE sWAT than in controls, we started by checking 
proliferation. As expected, proliferation was increased in 30-week-old RPE sWAT compared 
to wild-type. This is consistent with other reports showing that progerin-expressing cells 
undergo a hyperproliferative state before plateauing and entering senescence143,207. Similarly, 
proliferation was assessed in vitro, and we found that although only 5.15% of mouse 
preadipocytes were transfected with a vector conferring progerin expression, proliferation 
was significantly increased compared to cells transfected with an empty vector. Previous 
studies have indicated that the terminal differentiation process that gives rise to mature 
adipocytes was impaired upon progerin expression in various cell systems91,92. When testing 
the differentiation capacity in our in vitro model, we did not observe obvious microscopic 
changes between the different groups. Nevertheless, analysis of differentiation regulators 
showed that C/EBPα and LPL were downregulated in preadipocytes expressing both lamin A 
and progerin. Similar trends were observed in progerin-expressing cells. However, not all of 
the tested markers of differentiation were affected, which suggests that terminal 
differentiation might only slightly be altered in our conditions.  
Increased proliferation is known to contribute to cell cycle slowdown or even cell cycle 
arrest, which can lead to cellular senescence208. We performed gene expression analysis of 
various markers of senescence and SASP, which resulted in a shift towards higher 
senescence levels in 30-week-old RPE sWAT. This was further emphasized in 90-week-old 
mice where p16-positive cells were found significantly increased in RPE sWAT. It was also 
demonstrated that persistent DNA damage, another trigger of cellular senescence, was 
involved in the fat decline of a premature aging mouse model209. Furthermore, persistent 
DNA damage was also found in in vitro systems of HGPS67,144,169,210. Analysis of DNA DSBs 
showed a higher frequency of γH2AX-positive cells in RPE sWAT at 60 weeks. Interestingly at 
both 60 and 90 weeks, the number of cells presenting elevated number γH2AX foci was 
significantly higher in RPE sWAT than controls. 
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Apoptosis can be triggered by DNA damage but also by hyperproliferation207,211,212. We 
observed increased caspase-3 independent cell death in 90-weeks-old RPE sWAT compared 
to controls. Since adipocyte death attracts phagocytic macrophages, we performed a F4/80 
staining to detect macrophage infiltration in 60-week-old sWAT. This revealed a 2-fold 
increase in positively stained cells in RPE sWAT. This was further confirmed by transmitted 
electron microscopy in 90-week-old RPE sWAT. Systemic inflammation may occur with 
adipose tissue depletion as the tissue produces pro-inflammatory cytokines and adipokines 
capable of activating immune responses89,213,214. Systemic inflammation was found activated 
in RPE mice, with increased circulating levels of leukocytes and pro-inflammatory cytokines 
in 90-week-old mice. Taken together, all the defects present in our RPE mice sWAT (cell 
cycle deficiency, genomic instability, senescence, inflammation) overlap with common 
hallmarks of aging and HGPS1,61, suggesting that even present in only a small fraction of cells, 
progerin might still be able to contribute to tissue pathology and be implicated in normal 
aging. 
 Paper III. The Hutchinson-Gilford progeria syndrome mutation, LMNA 
c.1824C>T, is a somatic mutation in patients with chronic kidney 
disease. 
It appears that only a few progerin-expressing cells in a murine tissue may be capable of 
contributing to tissue pathology with aging. Even though progerin was present in a small cell 
fraction, its levels may not be physiologically relevant in the context of human aging. Hence, 
we asked the question of whether progerin is expressed and involved in human tissue 
pathology in aging-associated diseases. The fact that HGPS and CKD patients present an 
almost identical vascular phenotype led us to investigate the potential association of 
progerin with human early vascular aging (Figure 13). 
 
Figure 13. Graphical abstract of Paper III. In this study, epigastric arteries from CKD patients 
were scrutinized for the presence of progerin. Progerin was found expressed at the transcript and 
protein levels, in 70% of the patients and in up to 7% of the cells of the arteries, which was 
associated with activated DNA damage. Further analysis revealed that the most common HGPS 
mutation, LMNA c.1824C>T, was responsible for the observed progerin expression. 
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Study design 
Arteries were collected from CKD patients and controls, and classified into different 
calcification grades. Cell density was assessed along with the frequency of progerin positive 
cells in the tissue. Age-associated features such as proliferation, senescence and DNA 
damage were measured in those arteries. Arterial and blood DNA from CKD patients and 
controls was used to determine the somatic mutation in the LMNA gene that leads to 
progerin expression. Estimation of the effect of uremic serum was performed in vitro on 
human VSMCs, and the regenerative capacity of progerin-expressing stem cells was assessed 
by in vivo competitive transplantation of LmnaG609G/G609G and wild-type hematopoietic stem 
cells into wild-type mice recipients. 
Progerin expression in CKD arteries 
To determine the age-related vascular decline in our sample set, we assessed medial 
calcification and VSMC loss, two characteristics commonly observed in HGPS patients. 
Medial calcification was found correlated with increased CKD patient age, while reduced 
medial cell density was mostly seen in arteries displaying moderate to extensive vascular 
calcification. Surprisingly, screening for the presence of progerin at the protein level in 40 
CKD arteries revealed that 70% of the patients displayed a small frequency of progerin-
expressing cells in arterial media, forming clusters in some instances (ranging from 0.2 to 
7.4%). Contrastingly, only one out of six control arteries showed a low frequency of progerin 
positive cells (representing 0.2%), which is in agreement with previously reported data96. As 
prelamin A was previously found involved in accelerated vascular aging173,174, we tested the 
specificity of our antibody to make sure that we were not assessing prelamin A instead of 
progerin. Western blot analysis confirmed the specific affinity of our antibody to progerin. In 
addition, prelamin A staining of the CKD arteries did not uncover the presence of prelamin A 
expressing cells. Further investigation of progerin expression showed that progerin 
transcripts could be detected by ddPCR in all CKD arteries tested but was not apparent in 
control arteries. Progerin transcripts were even found in CKD arteries that did not display a 
positive staining for the protein, suggesting that our antibody detection of progerin may not 
be sensitive enough to uncover all expressing cells with low levels.  
To identify the mechanism responsible for such progerin expression in CKD, we analyzed 
the DNA of a control and 27 CKD arteries for the presence of the c.1824C>T mutation. The 
variant was detected in 16 of the patients’ samples, among which 13 were already found 
positive for progerin expression at the protein and/or RNA level. The control sample also 
carried the mutation and corresponded to the sample with 0.2% of progerin positive cells. In 
total, progerin was found at the DNA, RNA and/or protein levels in 85% of the CKD arteries 
(34/40) and 12.5% of the control arteries (1/8). Taken together, we have established that 
progerin is expressed in CKD arteries at low levels and in a small fraction of medial cells as a 
result of sporadic induction of the LMNA c.1824C>T. 
 
  35 
Activated DNA damage and moderate senescence in CKD arteries 
In an attempt to estimate the potential contribution of progerin expression to the CKD-related 
vascular decline, we then analyzed several cellular and molecular defects commonly 
associated with progerin expression. We did not find increased levels of caspase 3-mediated 
cell death nor any correlation between shortened telomere and increased frequency of 
progerin-positive cells. Analysis of senescence and SASP markers revealed a mild activation 
of vascular and systemic senescence. On the contrary, DNA damage was found to be 
increased. Analysis of the DDR markers ATR and 53BP1 showed a significant positive 
correlation between the increased number of progerin-positive cells and activated DDR 
signaling, thus suggesting that progerin expression may impact the levels of DNA damage 
occurring in CKD arteries, similarly consistent with previous reports demonstrating that 
prelamin A accumulation encourage persistent DNA damage in accelerated vascular aging173. 
Vascular regeneration as a mechanism of increased progerin expression? 
After assessing progerin expression and subsequent associated defects in CKD arteries, two 
questions remained. How is the LMNA c.1824C>T mutation generated? Where do these cells 
originate? In order to establish how the variant can be induced in the medial layer of CKD 
arteries, we performed an in vitro experiment on human VSMCs, our hypothesis being that 
the CKD uremic environment might be capable of engendering such specific mutation. While 
cells presented an increased number of DNA damage foci after uremic treatment, the LMNA 
c.1824C>T mutation was not detected. Strangely, the variant was observed in VSMCs before 
and after treatment with normal serum, suggesting that the uremic environment is not able to 
induce the mutation but rather negatively affect cells carrying that mutation. Our second 
hypothesis was that the LMNA c.1824C>T mutation is present in VSMCs progenitors that 
repopulate the tissue upon vascular damage. As previous studies have demonstrated that 
VSMCs can proliferate under vascular damage conditions215,216, we next addressed the 
proliferation status of CKD arteries. Proliferating cells were found in the medial and/or 
adventitial layers of nine CKD arteries out of 11, which suggested an increase in vascular 
regeneration, in agreement with extensive tissue damage. However, there have been debates 
in regard to what type of cells actually have the capacity to proliferate in arteries. Whether 
they are VSMC progenitors arising from the adventitial layer, dedifferentiating VSMCs or 
blood-circulating progenitors still remains unclear217-219. We next assessed the presence of the 
LMNA c.1824C>T mutation in blood from CKD patients and control, and found a significant 
increase in its fractional abundance in CKD vs. control blood. Progerin-expressing progenitor 
cell functionality and ability to propagate in a tissue were then evaluated by competitive in 
vivo transplantation of hematopoietic stem cells. This experiment revealed a significant 
increase in the initial proliferation of progeroid cells. This is in agreement with previous 
studies that have shown that the expression of progerin induces increased proliferation143,207. 
Additionally, this established that progerin-expressing transplanted cells do not undergo 
senescence even after an extended time but rather are functional and able to repopulate the 
hematopoietic system. Taken together, our data suggest that the mutation was present in 
VSMCs progenitor cells from the vascular wall, which were expanded and propagated as a 
result of the vascular regeneration that occurred following vascular damage in CKD. 
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 Paper IV. Sequence-specific inhibition of DNA damage response at 
telomeres improves the detrimental phenotypes of Hutchinson-Gilford 
progeria syndrome. 
There are a plethora of treatment strategies for HGPS that researchers have developed over 
the years. However, some remain at the research lab or preclinical stage and have not been 
assessed in the general human population, while others may have undesirable secondary 
effects or would probably barely improve HGPS symptoms. As of today, there is no perfect 
treatment for HGPS; the current FTI strategy moderately ameliorating the health and life 
expectancy of patients. Until a cure is found, there is a need to discover and test novel 
treatment strategies. Here, we hypothesized that targeting telomere dysfunction in HGPS 
may rescue the phenotype and potentially extend the lifespan (Figure 14). 
 
Figure 14. Graphical abstract of Paper IV. Analysis of postnatal day 6 HGPS mice skin showed 
telomere dysfunction characterized by the production of telomeric non-coding RNAs resulting in 
DDR activation. Treating HGPS mice with telomere-specific antisense oligonucleotides (tASOs) 
improved the telomere dysfunction phenotype and reduced the DDR. This positively impacted 
cellular senescence and the proliferative capacity of keratinocytes. Most strikingly, tASOs 
treatment extended the maximum lifespan of HGPS mice by 44%. 
Study design 
In this study, we first made the use of various in vitro systems expressing progerin at 
different levels. Telomere dysfunction was assessed, along with the consequences of DDR 
inhibition at telomeres using telomere-specific antisense oligonucleotides (tASOs). We then 
took advantage of a severe conditional HGPS mouse model with epidermal progerin 
expression. To determine the impact of tASOs treatment in vivo, pregnant mice were 
injected systemically at E17.5 and newborn pups received additional tASOs intraperitoneally 
every three days, starting at PD2. Pup body weights, external phenotype and lifespan were 
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recorded. Skin samples were collected at distinct ages and subsequently analyzed for 
telomere dysfunction. Effects of the tASOs treatment were measured in PD6 skin samples, 
including telomere dysfunction induced foci (TIFs), DDR signaling, senescence, proliferation, 
stemness, cell death and inflammation.  
In vitro assessment of telomere dysfunction and inhibition of telomeric DDR by tASOs 
Telomere dysfunction induces the transcription of telomeric non-coding RNAs (tncRNAs), 
which are essential for DDR activation and recruitment of DDR factors220. Here, we first 
showed that these tncRNAs are accumulated in progerin-expressing cells compared to 
control cells. Indeed, progerin expression triggered the production of both G-rich (teloG) and 
C-rich (teloC) strands of tncRNAs, accompanied by an increased number of TIFs. Inhibition 
of telomeric DDR using tASOs complementary to either strand of tncRNAs (i.e. anti-teloC and 
anti-teloG) rescued the number of TIFs in progerin-expressing cells, down to the levels 
observed in control cells. This phenomenon was followed by an improved proliferation rate 
and lower senescence, without altering progerin levels. These data indicated that telomeric 
DDR signaling is involved in the senescence and proliferative defects commonly associated 
with progerin expression. Hence, targeting telomere dysfunction with tASOs may be 
beneficial to HGPS patients, but such assumptions needed further testing. 
tASOs-specific inhibition of telomeric DDR in HGPS mice skin 
To determine whether telomeric DDR signaling is relevant to HGPS in vivo, we assessed the 
levels of tncRNAs in both HGPS and control mice skin. Both the G-rich and C-rich strands of 
tncRNAs were found to be significantly increased in HGPS skin. Analysis post-tASOs 
treatment revealed a significant decrease in TIFs in PD6 HGPS mice treated with anti-teloG or 
anti-teloC, while TIFs were found elevated in HGPS vs. wild-type mice receiving control 
ASOs. In a similar fashion, DDR factors (pKAP1 and 53BP1) were overall significantly 
reduced, particularly in anti-teloG-treated HGPS mice. Together, these findings show that 
telomere dysfunction leads to telomeric DDR activation in vivo, which can be drastically 
inhibited by telomeric sequence-specific ASOs. 
Improved healthspan in HGPS mice upon tASOs treatment 
We then analyzed proliferation and senescence to determine whether these could be 
rescued by tASOs treatment in vivo. Indeed, as demonstrated in paper I, these HGPS mice 
display elevated numbers of proliferative keratinocytes compared to wild-types, contributing 
to the observed disrupted tissue homeostasis. However, the pathological proliferation that 
occurs in the progeroid suprabasal epidermal layer was rescued upon anti-teloG treatment. 
P16-associated senescence was also found increased in the basal layer of HGPS skin but was 
significantly reduced by anti-teloG treatment. Together, these data implied an ameliorated 
tissue homeostasis. We therefore checked for improvements of pathological characteristics 
of these HGPS mice. Globally, tASOs treatments recovered both epidermal and dermal 
thickness, and anti-teloG treatment was particularly efficient in reducing epidermal 
hyperplasia and keratinocyte atypia. In addition, tASOs-treated HGPS mice presented a more 
preserved stem cell pool than control ASO-treated HGPS mice. In situ hybridization revealed 
a significant reduction of keratin 15 levels in HGPS vs. wild-type mice, whereas these levels 
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were found increased by 7-fold upon anti-teloG treatment of HGPS mice. Similarly, TUNEL 
assay showed less evidence of cell apoptosis/necrosis in tASOs-treated HGPS mice. Hence, 
these results support the fact that treatment with tASOs leads to a healthier tissue in HGPS. 
To further support those results, we sought for signs of inflammation and found a 
significantly reduced number of dermal pan-leukocytes upon tASOs treatment compared to 
control ASO-treated HGPS mice. Likewise, in situ hybridization and qRT-PCR analyses of 
inflammatory cytokines showed a significant decrease in IL-1α and IL8, IL-1α being localized 
mostly at the epidermal granular layer and IL8 in the dermis. Taken together, all these 
findings argue for an overall beneficial effect of telomeric DDR inhibition. 
Lifespan extension of HGPS mice  
As the mice were being treated with the different ASOs, body weights were recorded and 
showed no unusual weight loss, suggesting an absence of toxicity from the administration 
and that the treatment was well tolerated. Macroscopic assessment of the external 
phenotype showed that anti-teloG-treated mice presented with a better-preserved hair 
growth visible from PD8 in comparison to control-treated mice. As previously described, 
these HGPS mice present a severe phenotype resulting in a median survival of 8 days and a 
maximum premature death at PD9105. HGPS mice treated with anti-teloG had a significantly 
improved survival, with an increase of the median lifespan by 24% and of the maximum 
lifespan by 44%. This was remarkable given the severity of the model. HGPS mice treated 
with anti-teloC, on the other hand, did not show any change in survival. Indeed, anti-teloC 
treatment appeared to have a milder effect than anti-teloG treatment on all of the 
characteristics assessed, which is most likely due to a suboptimal biodistribution of anti-
teloC in the tissue. 
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5. CONCLUSIONS & PERSPECTIVES 
Paper I 
• We successfully demonstrated that progerin accumulation results in an aberrant shift 
towards symmetric cell division in vivo.  
• Progerin expression was associated with impaired stem cell function characterized 
by increased proliferation, but also with disrupted canonical Wnt/β-catenin signaling 
characterized by reduced β-catenin levels both in patient fibroblasts and a progeroid 
mouse model. 
• Accumulation of emerin at the nuclear rim and decreased levels of nesprin-2 were 
found upon progerin expression in in vitro and in vivo systems.  
In summary, we propose a model in which progerin accumulation indirectly alters the 
proper localization of nesprin-2 and leads to emerin accumulation via their potential 
interaction at the NE, which eventually disrupts the Wnt/β-catenin signaling pathway. This, in 
turn, may lead to an abnormal cell division process characterized by cell polarity bias and 
proliferation increase, thus disrupting epidermal homeostasis and ultimately resulting in 
stem cell exhaustion67.  
All those mechanisms might be intricately related to each other, and our evidence fit with 
previous reports. However, there persist some gray areas to explain how progerin directly 
triggers such events. Does progerin interact with and/or sequester emerin, therefore leading 
to its accumulation at the nuclear rim? Does progerin interaction with SUN1 proteins disrupt 
the LINC complex, which could explain nesprin-2 loss at the nuclear rim? Is the nuclear 
transportation of β-catenin really affected by emerin accumulation coupled to nesprin-2 
reduction? Could the non-canonical Wnt signaling, i.e. planar cell polarity pathway, also be 
involved in the observed impaired cell division? Is the gene expression downregulation 
observed in LRCs responsible for the increased proliferation of basal keratinocytes, or are 
other stem cells affected too? There remain plenty of questions to be thoroughly investigated 
in order to fully understand what are the downstream effects of progerin expression. It is by 
answering those questions and many other cellular and molecular-related questions that we 
will truly grasp the disease mode of action, which will allow scientists to develop better 
treatments for HGPS.  
Paper II 
• We have shown that progerin is present at very low levels in the adipose tissue of 
healthy individuals. 
• Several of the cellular and molecular hallmarks of HGPS and aging were found 
replicated in the adipose tissue of our RPE mice, including disrupted cell cycle, 
increased DNA damage and cellular senescence, and systemic inflammation.   
• We associated rare progerin-expressing cells with tissue decline over time. 
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In summary, we propose a hypothetical model to clarify how a low frequency of progerin-
expressing cells may lead to adipose tissue decline over time. Hence, persistent exposure to 
a small number of progerin-expressing cells initially provokes aberrant preadipocyte 
proliferation, which in turn is partly responsible for abnormal cellular development and 
senescence. Senescence is further activated as DNA damage accumulates, and propagates to 
neighboring cells in a paracrine manner through activation of the SASP phenotype, all of 
which ends up triggering cell death and thereby encourages macrophage infiltration. The 
immune response is ultimately activated by the pro-inflammatory environment of the 
adipose tissue, resulting in systemic inflammation.  
Our findings suggest that progerin expression in a small fraction of cells may participate in 
aging-associated pathologies. To fully understand whether a low frequency of progerin cells 
matters in the context of healthy aging, and if it contributes to aging-associated pathologies, it 
would be of interest to create a mosaic animal model. This could be achieved by using 
CRISPR/Cas9-based single nucleotide editing. Indeed, it was previously shown that injection 
of the base editor into rabbit pronuclear stage embryos to induce the HGPS mutation 
resulted in prematurely aged rabbits expressing progerin and displaying the typical HGPS 
phenotype221. Thus, neonatal injection of the base editor in mice could result in low 
efficiency of base conversion and therefore in a low frequency of progerin expressing cells 
in various tissues. Using a specific virus serotype would also allow for tissue-specific editing. 
A tissue-specific mosaic model of progerin expression would be of great use, allowing 
researchers to understand which tissues are particularly affected by progerin expression, 
starting with the cardiovascular system where progerin has previously been found during 
aging96. 
Paper III 
• We have established that progerin is expressed in a low frequency of cells present in 
the medial layer of CKD arteries. 
• The presence of progerin expression is caused by the most common HGPS mutation 
LMNA c.1824C>T. 
• Progerin expression correlates with a DNA damage phenotype.  
• Progerin expression may become more enriched by vascular regeneration, via 
proliferation and expansion of progenitor cells that carry the most common HGPS 
mutation. 
It is the first time that progerin expression is identified in CKD arteries at the RNA and 
protein levels resulting from the induction of the LMNA c.1824C>T variant. Nevertheless, the 
investigation of progerin’s contribution to accelerated vascular decline should be deepened. 
Indeed, we have demonstrated in this study that there seems to be an unusual proliferation 
ongoing in CKD arteries, but it is unclear if the proliferating cells are also expressing 
progerin, therefore, participating in clonal expansion of the progerin cell pool. The 
transplantation experiment seemed to show a competitive advantage of progerin-expressing 
hematopoietic cells, however, the relevance of such findings to vascular cells may be 
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contested and a more appropriate model and experimental setup could be used. In 2013, Liu 
and colleagues demonstrated that prelamin A promoted VSMCs calcification173. 
Accumulation of prelamin A leads to similar defects to the one observed under progerin 
accumulation. In addition, progerin was found in arteries during physiological aging, while 
other studies have shown the contribution of high levels of progerin expression to VSMC 
calcification and atherosclerosis96,98,100. Hence, it would be of interest to assess whether a 
small fraction of progerin-expressing cells (up to 7.4%), is able to induce vascular 
calcification. Finally, the use of an animal model with mosaic expression of progerin in the 
vasculature would also be of high significance in order to establish a role for progerin in the 
premature vascular aging observed in CKD.  
Paper IV 
• We have established that telomere dysfunction in in vitro and in vivo models of 
HGPS results in DDR activation via the production of tncRNAs. 
• Treatment with telomeric sequence-specific ASOs is able to repress the DDR 
signaling and reduce the number of telomere dysfunction induced foci in vitro and in 
vivo. 
• tASOs treatments are not only able to ameliorate both the senescent and defective 
proliferation phenotypes, but also to improve cell death and reduce tissue 
inflammation to some extent. 
• Anti-teloG treatment led to an astounding survival extension of HGPS mice. 
Hence, targeting telomere dysfunction appears as a promising approach to combat the 
detrimental effect of progerin expression. ASOs have proven to be a successful tool used in 
the treatment of various diseases. Some were previously designed and tested in HGPS, 
where the effects were also found beneficial73,138. Many ASOs are currently in advanced 
clinical trials, while others are already FDA approved. Since telomeric DDR is activated at 
dysfunctional telomeres most often during aging and cancer, it could therefore be assumed 
that tissue delivery would not be a problem, unlike other drugs, and that once administered, 
tASOs would only affect unhealthy cells.  
Future perspectives 
The road is long, but we might be closer to a cure for HGPS than we can imagine. With the 
constant development of scientific tools, research advances have grown substantially. 
Among the last technologies that recently emerged, base editing stands out as a potential 
candidate gene therapy for HGPS. Indeed, base editing is a new alternative to genome 
editing, allowing for the modification of a single DNA or RNA nucleotide, without creating 
double-stranded DNA breaks and resulting in less off-target effects222. Adenine base editing is 
able to convert an AT base pair into a GC base pair and would thus be particularly useful 
in the case of HGPS, in order to correct the most common point mutation, LMNA c.1824C>T, 
from a thymine to a cytosine. Therefore, base editing appears like a wonderful technology 
for the future of HGPS. Base substitution in only 10 to 20% of the cells might yield 
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encouraging results, probably considerably slowing down the progression of HGPS and 
increasing the life expectancy of patients. Tailoring the delivery system to efficiently target 
specific organs responsible for the most lethal aspects of the disease such as the 
cardiovascular system, may help to attain such goals.  
In the meantime, we have shown that the use of antisense oligonucleotides targeting 
telomere dysfunction is able to substantially improve the healthspan and lifespan of a severe 
progeroid mouse model. Such promising treatment should be tested in other available 
mouse models such as the systemic LmnaG609G mice to further assess its potential. But tASOs 
therapy may not only be useful for ameliorating HGPS condition, but could also potentially 
be applied to other age-related pathologies with telomere deficiency. The fact that CKD and 
HGPS patients have a common vascular phenotype characterized by early vascular aging, 
and that we found the LMNA c.1824C>T mutation and progerin accumulation in CKD arteries, 
suggests that current HGPS therapies could potentially be applied to this disease. Actually, 
FTIs, which are commonly used to treat HGPS patients, were previously found to 
significantly inhibit calcification in vascular smooth muscle cells223. Besides, we have shown 
that not only progerin is able to disrupt tissue homeostasis when overexpressed but also 
that a few progerin positive cells in a tissue could lead to detrimental pathology with aging. 
In addition, it is known that progerin mostly affects tissues such as skin, bones, adipose 
tissue and the cardiovascular system. Thus, screening for progerin expression and its 
associated mutation in age-associated diseases characterized by deficits in those tissues, 
such as osteoporosis or other cardiovascular diseases, could possibly open new paths for 
novel treatment strategies of more common disorders.  
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